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Abstract 
In the present work an attempt was made to elucidate some 
aspects of the biological events involved in the anti-inflammatory 
activity of peptide 401. The already described biological properties 
of peptide 401, isolated from the venom of the common European honey 
bee (Apis me11ifera) are its ability to degranulate mast cells and to 
a,ct as a potent anti-inflammatory agent in the rat. Very little is 
known, however, regarding the details of its mode of action. This 
problem was approached in the following ways: 
a) by determining if, like many of the non-steroidal anti-inflammatory 
agents, peptide 401 was able to inhibit prostaglandin synthesis, 
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using for this a purified enzymatic complex, prostaglandin synthetase, 
obtained from sheep seminal vesicles. 
b) by investigating if there was any preferential binding of peptide 
401 to the rat leucocytes, which are important intermediates in 
the inflammatory model used to assess the anti-inflammatory activity 
of peptide 401. Investigation on the interactions between peptide 
401 and model membrane systems (liposomes) was also carried out in 
order to establish what major features of these model membranes 
would be important for the binding of peptide 401 and its relevance 
to the situation in vivo. 
>c) by investigating it the anti-inflammatory actiVity of peptide 401 
could in any way be explained by stimulation of synthesis and 
release of corticosteroids by adrenal cells of rats. 
d) by studying the possib1e interference of peptide 401 with lymphocyte 
maturation or with the unspecific PHA stimulation of lymphocyte 
maturation, since the lymphocytes appear to play an important role 
in the rat adjuvant arthritis, a model of inflammation in which 
peptide 401 also shows therapeutic action. 
It was concluded that the anti-inflammatory activity of 
peptide 401 could be explained, at least partially, by inhibition of 
prostaglandin synthesis, since this was demonstrated in vitro. Such 
a conclusion was supported by the observation that a modified peptide 
ŸÕŨĚ (labelled with dansyl) seems to present a certain degree of 
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specificity concerning its binding and/or absorption by the rat 
polymorphonucleocytes, which are one of the major sources of prostaglandins 
being formed during the carrageenan oedema. Peptide 401 did not show 
any direct action on rat adrenal cells regarding corticosteroid 
production, and it did not significantly influence the maturation of 
rat lymphocytes. 
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CHAPTER 1 
GENERAL INTRODUCTION 
The present work is an investigat'ion into the mode of action 
of an anti-inflammatory peptide isolated from the venom of the common 
European honey bee (Apis mellifera). This peptide has been named peptide 
401. The classification 'anti-inflammatory' derives from the observation 
that peptide 401 is able to reduce the swelling caused by injection of 
carrageenan into the foot pad of rats (rat paw oedema test) and reduces 
or prevents the swelling in a condition known as adjuvant arthritis. 
Before the pharmacological properties of peptide 401 can be 
evaluated, the experimental models of inflammation must be compared 
with the naturally occurring inflammatory processes. 
1-1 ' The inflammatory process 
The process of inflammation consists Of' a series of events by 
means of which an organism is able to defend itself against invasion by 
other living forms and also to promote tissue repair following injury 
which can be immune, mechanical, chemical or thermal. The degree of 
complexity of such a fundamental process can be appreCiated by 
considering the number of specialised systems involved and the control 
mechanisms necessary to coordinate them. An understanding of the 
phenomenon'is complicated by the fact that the manifestations associated 
with the inflammatory process vary depending on the causal agent and on 
the species being studied. Thus, responses following bacterial infection, 
which eventually involve the immune system and lead to cytotoxic reactions, 
must be distinguished from cases where there is no participation ot 
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foreign bodies such as in aseptic trauma or in some thermal lesions. 
Thus, despite the fact that inflammation has been investigated for 
many years, it is only possible to recognise some common patterns 
accompanying injury, such as redness (erythema), swelling (oedema), 
pain, fever and in some cases loss of function of the tissue affected, 
and some of the agents which are responsible for causing and maintaining 
these symptoms. Therefore, in the following summary, a sequence of 
events which occur in the majority of inflammatory processes will be 
described, from the onset of the inflammatory (acute phase), to the less 
understood chronic states. It must be kept in mind, however, that such 
a description is only a rough apprOximation to the in vivo situation 
and it does not take into account the individual cases of inflammation 
which diverge from the general picture. 
1-1-1 Vascular events during inflammation 
Following injury, the first evident responses are associated 
with a locally increased vascular permeability at the level of 
capillaries and venules of the affected tissue' (107). Although the 
vascular response is prominent immediately after the inflammatory 
stimulus, the affected tissue must be considered as a whole concerning 
the response and it is only because. the vascular manifestations are more 
obvious that these aspects of the inflammatory ŮŲŬȘŤŸVĚhave been 
described in more detail. The increased vascular permeability, which 
can be measured by accumulation of dyes or isotopically labelled 
proteins at the inflamed tissue is believed to be due to contraction of 
the adjacent endothelial cells of the venules, which leads to formation 
of gaps between the cells. As a consequence extravasation of plasma. 
occurs and proteins escape into the interstitial space, while small 
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particles and cells are retained by the basement membrane (114). The 
pressure for this filtration is greater than the osmotic pressure of 
the plasma, probably due in part to the increased blood flow to the 
affected area as a consequence of local vasodilatation (9). The fluid 
. 
which has extravasated into the inflamed area together with an 
obstructed venous outflow contributes to oedema formation (206). The 
lymphatics appear to play an important role in draining the excess of 
protein and fluid (107). 
1-1-2 Mediators of increased vascular permeability 
The immediate increase in vascular permeability which occurs 
within minutes and lasts for up to 1 hour is believed to be mediated 
by histamine, although in the rat, 5-hydroxy tryptamine (serotonin) 
seems also to be an important mediator ĜÍÌĲĞŸĚ Local injections of 
histamine induce increased vascular permeability and pretreatment of 
the animal with anti-histamines, which block the histamine receptors 
suppresses this early phase of inflammation. The main sources of 
histamine are the tissue mast cells which are abundant around vascular 
and connective tissues, platelets and basophiles. Histamine, which is 
believed to be synthesized in vivo by enzymatic decarboxylation of 
histidine (152), is stored in the granules of the mast cells, probably 
complexed to heparin and a protein (190). The release of histamine 
occurs either as a result of degranulation without cell destruction, in 
which case' all the contents of the granules are also released, or it 
can be actively and specifically secreted from the mast cells without 
degranulation (159, 160). Under some circumstances the contents of 
the granules are released into the extracellular space as a consequence 
of cell lysis. Such cases are denominated cytotoxiC •. A number of 
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basic peptides are able to induce degranulation of mast cells as is 
the synthetic polyamine called compound 48/80. Depletion ot histamine 
by pretreatment of the animal with compound 48/80 leads to a suppression 
of the early phase of increased vascular permeability in the Same way 
as pretreatment of the animal with anti-histamines. The mechanisms 
controlling mast cell degranulation are poorly understood but it seems 
, ++ 
that in most cases an intracellular inflow of Ca ions is a 
requirement (68). Likewise it is not known what factors in the 
inflammatory process impair further release of histamine after the 
acute phase. It has been shown that a mechanism of feed-back control 
caused by histamine itself may be important in this regulation (30). 
Prostaglandins may be involved in the control of immunological release 
of histamine (168). 
The fact that anti-histamines suppress the increase in 
vascular permeability only during the initial phases of the inflammatory 
process suggests the participation of other mediators. These 'substances 
have a more prolonged effect than histamine in increasing the vascular 
permeability. It has been shown that the delayed phase of inflammation 
is associated with the kinins, of which b'radykinin has been the most 
studied (140, 183). The kinins are polypeptides containing 9-11 amino 
acid residues. They are generated by proteolytic enzymes (kallikreins, 
trypsin and pepsin) acting on plasma glycoprotein substrates. The 
kinins, which are able to produce slow and prolonged contraction of 
smooth muscle, are quickly catabolized in vivo, which makes their 
isolation from inflammatory exudates very difficult. It was only after 
chemical synthesis of WUŤŸŤĚpeptides and the development of suitable 
experimental models of inflammation, that their role as mediators of 
increased vascular permeability became established. 
11 
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Another group of vasoactive peptides which are believed to 
participate in the inflammatory process are the so-called leucokinins. 
These peptides are produced by proteolytic enzymes present in the 
leucocytes acting on a plasma protein precursor different from that 
of the kinins (183). 
Following the kinin phase, the events occurring in the 
inflamed tissue appear to be mainly mediated by the prostaglandins. 
The participation of prostaglandins in the inflammatory process will 
be discussed in Chapter 3. 
1-1-3 Cell migration and lysosome release 
It is during the so-called prostaglandin phase that leucocyte 
migration to the site of inflammation occurs. The leucocytes are able 
to adhere to the endothelial interfaces of the small blood vessels and 
then migrate across the membrane into the interstitial space of the 
affected tissue. It is not known what factors control the sticking of 
leucocytes to the vascular endothelium after tissue damage or their 
. ++ ++ 
migration across the membrane, but presumably Ca and Mg are 
involved (12). It is believed that prostaglandins, released at the 
site of inflammation may contribute to leucotaxis (leucocyte chemotaxis) 
(196), although this role of prostaglandins is still not certain since 
in vitro experiments have demonstrated that the leucotactic activity 
of prostaglandins is not very impressive when compared with other 
chemotactic agents such as casein (183). Although the type of leucocyte 
which migrates to the affected tissue has been the subject of much 
controversy, it is generally assumed that polymorphonucleocytes 
predominate in the acute cases, whereas in more chronic states the 
monocytes constitute the. majority of cells infiltrating around the 
affected area (78, 107, 127, 188). In rheumatoid arthritis, a chronic 
inflammation of the jOints, however, the synovial fluid contains a 
large number of neutrophils (205). At the site of inflammation the 
leucocytes then release their lysosomal enzymes which are mainly 
hydrolytic and capable of digesting a variety of intracellular and· 
extracellular macromolecules. Among the lysosomal enzymes released 
by the leucocytes are acid and neutral proteases which act on peptides, 
elastase, ŸĚ-glucuronidases acting on the links between N-acetyl 
.. 
muramic acid and 2-acetamido-2-deoxy-D-glucose residues of 
mucopolysaccharides (common constituents of bacterial wall membranes), 
collagenase, acid phosphatase and ŸĤŠÜXŨŠVŤĦĚ These enzymes are 
responsible for the tissue damage associated with chronic inflammatory 
states and several of the manifestations observed during inflammation 
could also be attributed to the secreted products Of the leucoeytes. 
The recognized inducers of lysosome release include the immunoglobulins, 
a number of baSic peptides and proteins (including peptides originated 
from the complement, called anaphylatoxins) and some proteolytic 
enzymes. In some cases the stimulus for lysosome release can be the 
interaction between the cells themselves as happens between basophiles 
and platelets (75, 85). In rheumatOid arthritis, the discharged 
lysosomal enzymes from neutrophils are believed to be associated with 
the phagocytosis of particulate material'and immune complexes (205). 
The release of lysosomes can also occur as a consequence of cytotoxic 
processes, which are generally characteristic of antibody action against 
the cells, in the presence of complement. Another example of cytotoxic 
release of cell products ÙŸĚcell lysis atter ŮŸŠŦŬȘXWŬVÙŐĚof compounds 
such as urate crystals, which form hydrogen bonds with the lysosomes 
intracellularly (187). It is possible that such is the situation 
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occurring in cases of gout. 
The participation of monocytes is usually associated with 
chronic states of inflammation. These inflammatory processes can last 
for several months or sometimes years, and in such cases the affected 
tissue undergoes changes which frequently impair its normal function. 
Macrophages are found in great numbers around the inflamed· tissue, 
together with connective tissue, which generally surrounds the area 
forming what is known as a granulomatous inflammation. The macrophages 
present in the granuloma are intensively engaged in phagocytosis and 
digestion of foreign material which can be of bacterial or parasitic 
origin. Materials such as silica, asbestos, beryllium and carrageenan 
can also induce the same process (127). In some cases, some bacterial 
products, and carrageenan can remain undigested inside the cytoplasm 
of macrophages for long periods of time. 
The lymphocytes are usually involved in 'the inflammatory 
process whenever antigens are present; they can act either as direct 
cytotoxic agents, by means of direct cell/cell contact following 
antigen stimulation (34) or by releasing factors known as lymphokines 
when T lymphocytes are involved (thymus derived lymphocytes), or 
lYmphokines and immunoglobulins when B lymphocytes (bone marrow derived 
lymphocytes) are involved. The lymphokines are able to attect a number 
Of different systems and can cause effects such as an increase in 
vascu.lar permeability, stimulation of lymphocyte mitosis, activation 
of macrophages and others (64). The role of lymphocytes will be 
discussed in more detail in Chapter 6. 
1 - '('wt 
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1-2 Experimental models 
The anti-inflammatory activity of peptide 401 was assayed 
in the rat paw carrageenan oedema and also in adjuvant arthritis. 
1-2-1 The rat paw carrageenan oedema 
The carrageenan oedema, introduced by Winter et ale (198) 
was the experimental model in which peptide 401 was first shown to have 
anti-inflammatory activity. This is a very popular assay method for 
anti-inflammatory drugs and is used for studies on the mediators of 
inflammation. It is induced by injecting carrageenan into the plantar 
region of the rat's hind paw. ,The injected paw gradually swells due to 
the irritant properties of carrageenan and the volume of the paw can 
be measured by a variety of techniques. 
volume displacement of mercury (198). 
One of the most ŤÜŮŨŬXŸTĚuses 
After a given interval of time 
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the volume of the uninjected paw is subtracted from the volume of the 
injected one and this value is used as the equivalent to ŨÕŸĚswelling; 
the potency of the drugs being tested is then measured as the percentage 
of inhibition of swelling. 
Carrageenan consists of a mixture of polysaccharides 
(sulphated galactose units) which is obtained from the Irish sea moss 
(chondrus crispus), although other seaweeds contain materials with 
s1m1lar structural characteristics and biological properties. Two 
main components have been fractionated from the polysaccharide mixture: 
K-carrageenan and A -carrageenan. K-carrageenan turns into a gel in 
the presence of potassium and A-carrageenan is not affected. The 
units ȘŬŸŮŬVÙŪŦĚOĤȘŠŲŲŠŦŤŤŸŠŪĚare sulphated D-galactose and 3,6-anhydro-
D-galactose and in ).. -carrageenan there are almost only sulphated 
D-galactose residues. The fraction which is more effective as an 
16 
irritant is. A ĤȘŠŲŲŠŦŤŤŸŠŪĚ·(47). 
After sub-plantar injection of carrageenan into the rats, 
the observed gradual swelling of the rat's paw is not uniform with 
time, that is, more than one phase can be distinguished when the 
swelling of the paw is plotted against time (166). Such a multi-
phase curve is an indication of the participation of more than one 
mediator. This is supported by the observation that several anti-
inflammatory agents were able to abolish some phases of the oedema 
but not completely suppress it, when injected separately into the rats. 
The work of Di Rosa et ale (48, 49) showed that in the rat carrageenan 
oedema, the several observed phases of the induced inflammatory process 
could be correlated to the sequential release of some mediators of 
inflammation. ThUS, by injecting antagonists of histamine and 
. 
serotonin, depletion of kinins and granulocytes and injection or oral 
administration of inhibitors of prostaglandin biosynthesis it was 
possible to evaluate the contribution of each mediator to the 
maintenance of the oedema. According to these authors the sequence 
of mediator release in the carrageenan oedema is the following: 
o 1.5 h release of histamine and serotonin 
1.5 h 2.5 h kinins 
2.5 h 6 h prostaglandins. 
. . 
Cell migration to the site of inflammation was 'shown to occur 
concomitantly with the appearance of prostaglandins at the site of 
inflammation. Although it was not possible to determine if the 
migrating cells were releasing the prostaglandins or if they were 
_released by the cells of the affected tissue, it was shown (115) that 
polymorphonucleocytes are able to release prostaglandins during 
phagocytosis. 
17 
The participation'of the complement system seems also to be 
a requirement throughout this induced inflammatory process since it 
was shown that in complement-depleted rats the oedema was suppressed 
for 6 h after injection of carrageenan (48). Although the carrageenan 
oedema shows many common features with ÙŪȚŨŸÜÜŠWÙŬŪĚof several other 
ethiologies, it should be pOinted out that carrageenan is able to induce 
side effects such as hypersensitivity to cold in rats, diarrhoea, 
ulceration of colon and loss of weight in rabbits and guinea pigs and 
ŠŪWÙĤȘŸŠŦẀŨŠŪWĚactivities (47). 
1-2-2 The rat adjuvant arthritis 
Peptide 401 was also shown to effectively reduce the swelling 
Of paws of rats with induced adjuvant arthritis (27). In this model 
of inflammation, which is considered to be a pathological condition of 
immunological origin, the paws of rats are injected with killed 
mycobacterium tuberculosis and Freund's adjuvant. After several days 
a general inflammatory process takes place which has some similaritiea 
to human rheumatoid arthritis although the severity of this systemic 
inflammatory model is so pronounced and induces so many radical 
changes in the rats, such as acute loss of weight, swelling of fore 
paws, ears, tail and joints, together with what appears to be an 
·1nfection of the respiratory tract (166, 129) that comparison is. 
difficult. However, with the possible exception of inflammatory models 
Where carrageenan is directly injected into the knees of rabbits (119), 
the rat adjuvant arthritis is considered to be the closest model 
available to the human rheumatoid arthritis (182). 
The first lesions which can be observed are the oedemas with 
infiltration of monocytes, mainly lymphocytes. Elimination of or 
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alteration in the lymphocytes induced by means of lymphocytotoxic 
drugs, alleviates or prevents the arthritic syndrome (166). The 
implications of the role of lymphocytes in the rat adjuvant arthritis 
and the 'anti-arthritic' activity of peptide 401 will be considered 
in Chapter 6. 
After the oedema formation, synovial proliferation occurs, 
with fibrin deposition and increased proliferation of fibroblasts and 
osteoblasts which actuallY' increase the size of the bone structures. 
The increased proliferation of connective tissue leads to formation of 
granulomas, which then spread and invade the joints. 
Among the common features between the induced rat adjuvant 
arthritis and the human rheumatoid arthritis, are the granulomatous 
swellings which progressively destroy the jOints, monocyte infiltration 
and the doses of non-steroid and steroid anti-inflammatory TŲẀŦŸĚwhich 
'are able to affect the course of the swelling. 
1-3 Biological properties of peptide 401 
. I 
Mast cell degranulating activity 
I 
During the systematic investigation of the components of the 
venom of the honey bee (Apis mellifera), Breihaupt et ale (31) isolated 
a peptide which proved to be very active in degranu1ating mast cells. 
For this activity the peptide was called MCDpeptide (mast cell, 
degranulating factor). The mast cell degranulating activity of this 
peptide was found to be comparable with that of compound 48/80, and the 
observed vasodepressor response which occurred in rats after intravenous 
injection of MCD seemed to be reflecting an action of MeD on histamine 
and serotonin release by the mast cells. It was noticed that when 
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compound 48/80 was injected repeatedly into the rats prior to injection 
of MeD, the vasodepressor activity of MeD was depressed. The same 
effect could be obtained when the animal was pretreated with MeD 
followed by injections of 48/80, indicating that the vasodepressor 
effect was mediated by the same agents, presumably histamine and 
serotonin. No lytic effects of MeD on red cells could be seen. 
1-3-2 Primary structure of peptide 401 
Working independently, the group of Vernon et al. (177) 
isolated a peptide from a preparation of crude venom of the same species 
of bee. This peptide was called peptide 401. Upon analysis of the 
amino acid sequence, the primary structure of peptide 401 was found to 
be identical with that of MeD, as established by Raux (82). The primary 
sequence of peptide 401 is the following: 
C'lS -
's 
AnG- LYS - ILE- CYS- GLY-LYS-ASN. NH 2 5 
\ 
ĦŸĞĚ
'5 , 
\.'{S .... CYS- ASN-
31' - 1 'VA 5lH ,. 
51 
I 
CYS 
.\ 
r 
-< 
Ul 
corresponding to a molecular weight of 2628. It contains no acidic 
amino aCids and 9 basic amino acids and thus is a highly basic peptide 
and will be strongly positively charged under physiological conditions. 
The position of the S-S bridges was determined by the group ot Vernon 
et al. (177). 
ĤĤĤĤĤĤĤĤĤŸĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤ _ .. -
- ĤĤĤĤĤĤĤĤĤĤĤĤĤĤŸĤĤĤĤĤĤĤ
1-3-3 Anti-inflammatory activity of peptide 401 
When peptide 401 was tested for anti-inflammatory activity, 
using the rat paw carrageenan oedema as an anti-inflammatory model, 
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it was found to have a potency comparable with that of other well known 
anti-inflammatory agents (27). Recently a more detailed study on the 
mast cell degranulatingactivity of peptide 401 has been carried out 
(13). Histamine release from mast cells by peptide 401 was found to 
++ be independent of extracellular Ca • It was temperature and pH 
dependent with an optimum activity at the physiological conditions. 
Cytotoxic ŤȚȚŤȘWŸĚon mast cells, as shown by the presence of LDH in 
the supernatant (lactodehydrogenase is a cytoplasmic enzyme and its 
release into the extracellular space indicates structural changes on 
the membrane, usually when lytic processes are occurring), were only 
perceptible at peptide 401 concentrations of 0.1 mg/ml. Peptide 401 
is able to induce mast cell degranulation at concentrations of 0.001 
mg/ml. Peptide 401 was also able to induce histamine release from rat 
leucocytes although with much less potency than its action on mast 
cells. No histamine release from human leucocytes could·be observed. 
These results together with the ion requirement for histamine release 
from mast cells led to the suggestion that peptide 401 and compound 
,48/80 share a similar mechanism of action on the mast cells (11, 13). 
It was suggested that the ability of peptide 40l to 
degranulate .mast cells was not connected to the anti-inflammatory 
effects since compound 48/80 and melittin, another basic peptide isolated 
from bee venom, which are able to degranulate mast cells did not have 
any anti-inflammatory activ.ity (27). Furthermore it 'was also established 
(27) that the anti-inflammatory activity of peptide 401 was not affected 
when the rats were pretreated with antagonists of histamine and serotonin. 
----- .-....... ĤĦĤĦĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤŸŸĤ.. 
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The ma·st. cell degranulating activity of peptide 401 does in fact give 
it a pro-inflammatory action which is reflected by the increased 
vascular permeability observed locally after intradermal injection of 
peptide 401 in the rats. The anti-inflammatory activity of peptide 401 
does not seem to be dependent on production and release, of cortico-
sterOids or catecholamines from the adrenal glands, since it persists, 
although somewhat reduced in adrenalectomized animals (27). The 
poSsible involvement of corticosteroids in the anti-inflammatory 
activity of peptide 401 will be considered in Chapter 5. 
Further work on the anti-inflammatory properties of peptide 
401 carried out', by the group of Hanson et ale (81), established the 
following points: 
1 Peptide 401 was able to suppress the local increased vascular 
'permeability induced by pistamine, bradykinin, serotonin and prosta-
glandins, as measured by accumUlation of labelled albumin at the site 
of inflammation. 
2 Antagonists of histamine and serotonin were able to block the 
local inflammatory action of 401 which is presumably due to an indirect 
.. 
action of 401 on the mast cells, but the anti-inflammatory activity of 
J 
401 was not affected by pre-treatment of the animal with those 
antagonists. 
3 The anti-inflammatory activity of 401 was not suppressed by local 
denervation and did not seem to be mediated by catecholamines and 
corticosterOids. 
4 No effects of peptide 401 on tissue perfusion could be observed 
86 
as shown by intravenous injection of Rb followed by collection and 
counting of various tissues, measurement of skin temperature and blood 
flow in the perfused mesentery. 
Although there was, no indication that peptide 401 has any 
vascular effects, the authors concluded that the anti-inflammatory 
activity of peptide 401 could be explained by an action on the rat 
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blood vessels. By somehow interacting with the blood vessels, peptide 
401 would be rendering them unresponsive to inflammatory agents liberated 
during the carrageenan oedema. However, this suggestion, besides 
implYing a local action of peptide 401 at the level of the rat's 
capillaries and venules either around the inflamed tissue or systemically, 
which is unlikely, cannot account for the therapeutic action of peptide 
401 in the adjuvant arthritis condition, since in this inflammatory 
model the lesions involved must certainly transcend the vascular level. 
1-4 Aims of the present work 
The experiments described in the present work were attempts 
to investigate possible mechanisms of action of peptide 401. Peptide 
ÏŸÍĚand melittin were first purified from the crude bee venom, as 
described in Chapter 2. Melittin was purified and used as a control 
in some experiments since it is also a very basic peptide with a 
molecular weight close to that of peptide 401. Melittin shows no 
anti-inflammatory activity although it shares with peptide 401 the 
ability to degranulate mast cells. 
Since many non-steroid anti-inflammatory agents have been 
found to inhibit the synthesis of prostaglandins, it was reasoned that 
peptide 401 could exert its anti-inflammatory effects by means of a 
similar mechanism. These experiments are described in Chapter 3. 
In Chapter 4, the ŮŬVVÙŞÙŸÙWXĚthat peptide 401 could interact specifically 
with the rat leucocytes was considered, and the experiments done in order 
to test this involved the use of a modified peptide 401 (dansylated). 
Model membrane systems (liposomes) were also used in order to establish 
if the lipid composition of the membranes was important for the binding 
and consequent action of peptide 401. The experiments described in 
Chapter 5, were carried out to test if peptide 401 could directly 
stimulate the synthesis and release of corticosterone by the adrenal 
glands of rats. The last chapter describes the experiments in which 
peptide 401 was investigated for its possible influence on the 
activation of lymphocytes, an effect that ŴŬẀŨŸĚbe relevant to the 
therapeutic action of peptide 401 on the more chronic conditions of 
inflammation such as in the induced adjuvant arthritis. 
. .' 
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CHAPTER 2 
PURIFICATION OF PEPTIDE 401 AND MELITTIN 
2-1 Peptide 401 . " 
The original bee venom as obtained from Bulgaria was 
processed there in the following way: the venom, collected on a glass 
plate was dried in the sun and scraped off. This powder was dissolved 
in water and filtered through filter paper. The filtrate was then 
freeze-dried and the resulting powder was dissolved in 0.1 M formic 
acid and subjected to force dialysis through cellophane tubing 
" 0 (8/32 Visking) for 72 h at 4 Co The solution outside the dialysis 
tubing was freeze-dried and used as the starting material for the 
purification of peptide 401 and melittin. 
The" first stage of separation was done in this laboratory 
by means of two K 50/100 columns, packed with Sephadex G 50 SF, 
equilibrated with 2% acetic acid (v/v). The gel was washed several 
times with 2% acetic acid prior to packing. A flow of 100 ml/h was 
maintained by means of a peristaltic pump for at least 24 h before 
application of the samples. The samples applied on the columns 
consisted of ŨŸĚ(w/v) solutions of the starting material dissolved 
in 2% acetic aCid. Samples of 3-5 g were applied at each time, 
amounting to a total of 15 g. 
The elution pattern obtained after this first step is 
depicted in Fig. 2-1. The separation of the eluate as described in 
Fig. 2-1 was based on the spectra of the several peaks, taken on a pye 
Unicam SP 800 ultraviolet spectrophotometer. The spectrum of fraction 
II indicated the absence of aromatic groups and tryptophan. Fraction 
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II was then evaporated to about 3-4 % of its original volume, using a 
Buehl Rotavapor-R system. The concentrated solution was then freeze-
dried) yielding a white powder weighing 1.12 g. This corresponded to 
8% of the original weight applied to the Sephadex G 50 columns. 
+ Fraction II was dissolved in 10 ml of 0.2 M Na acetate buffer 
pH 4.2 and applied on a column of Sephadex SP G 25, a cation exchanger, 
+ 
which was equilibrated with the Na acetate buffer. Prior to use the 
Sephadex gel was washed several times with the starting buffer and 
packed into a column measuring 24 x 40 mm. The buffer was pumped through· 
the column until the pH of the effluent solution was equal to that of 
the buffer. The flow rate was ŸÕĚml/h. After the sample had been 
applied, at least one column volume of the buffer was pumped through 
before the NaGl gradient started. The system used is described in 
Fig. 2-2. Beakers A and B were identical in size and volume. Vessel 
+ A contained aIM solution of NaGl in the 0.2 M Na acetate buffer pH 
+ 4.2. Vessel B contained the 0.2 M Na acetate buffer. Both containers 
were connected by means of thick tubing filled with the dilute buffer 
+ 
solution (0.2 M Na acetate pH 4.2). Fig. 2-3 shows the elution pattern 
thus obtained. 
The above fractions were collected and roto-evaporated. Each 
of the concentrated solutions obtained after evaporation was then 
applied to a column (24 x 60 mm) packed with Sephadex G 25 F, eqUilibrated 
with 5% acetic acid, for desalting. The presence of Gl- ions in the 
eluates of the G 25 F column was detected by ŸTTÙWÙŬŪĚof drops of a 
AgN03 solution to aliquots of the fractions and observing foro 
precipitates. The Cl- free fractions were then rota-evaporated and 
freeze-dried. The weights of the freeze-dried fractions were: 
IIa - 0.376 g, lIb - 0.061 g, IIc - 0.0866 g, lId - 0.0297 g, lIe 
"-, 
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. 
0.642 g, IIf - 0.234 g. 
A small sample of the above fractions was diluted in water 
to a concentration of 0.1 ÜŦIŸŨĚand applied to cellulose TLC plates. 
The plates were developed overnight in a solvent system consisting of 
n-butanol : pyridine: acetic acid: water' (90:60:18:72 v/v). The 
plates were then dried at room temperature, sprayed with a ninhydrin 
solution and placed in an oven for 5 min at 750 C. Fig. 2-4 shows the 
separation obtained. Fraction IIa was discarded since it did not bind 
to the Sephadex SP C 25 gel; fraction lIb was also discarded because it 
was not ninhydrin positive. 
Fractions IIc - lIt were analysed for N-terminal amino acids, 
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using the dansyl chloride method, as follows: to samples of the peptides' 
dissolved in water, 10 ŸŨĚof a 0.2 N Na2C03 solution was added; this 
solution was then ŤẂŠŮŬŲŸWŤTĚto dryness. Afterwards 7 ŸŨĚof water and 
7 ŸŨĚof an acetone solution of dansyl chloride (final concentration of 
2.5 mg/ml) was added and left to stand tor Ih at room temperature • 
. 
The contents of the tubes were dried and 50 ŸŨĚof 6N Hel was added to 
hydrolyse the dansyl-peptides. The tubes were sealed and placed in an 
oven at 1050 C overnight and then 5 ŸŨĚof 5a,% pyridine (v/v) was added 
• and from this solution 0.25 ŸŨĚwas applied to polyamide TLC sheets. 
The sheets were first developed using a solvent system consisting of 
1.5% formic acid (w/v) in water. The second run was made by turning 
o the sheet through 90 and developing it in a solvent system consisting 
of benzene : acetic acid (9:1 v/v) followed by ethyl acetate : methanol 
acetic acid (20:1:1 v/v). Standard dansyl-amino acids were also 
developed in the same way. The sheets were then observed under UV 
light. The results were the following: Fraction IIc - Tyr, fraction IId 
- GLY, VAL, fraction lIe - ILE, and traction IIf - GLY. 
'. 
· ,FI G 2·4 - Thin layer chromatography of samples from 
fra.ction II 
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Fraction lIe was tested in the rat paw carrageenan oedema 
assay and shown to have a potent anti-inflammatory activity. When 
fraction lIe was incubated with rat mast cells it produced intense 
degranulation. Therefore fraction lIe consisted of peptide 401. 
2-2 Melittin 
Fraction I (see Fig. 2-1), weighing 2.644 g, was applied to 
a ,K 50/100 column packed with Sephadex G 50 SF equilibrated with 2% 
acetic acid. The fractions which were eluted did not separate very 
well and so they were recombined, roto-evaporated and applied On a 
, + 
Sephadex SP C 25 column equilibrated with 0.6 M Na acetate buffer 
pH 4.2. A gradient of NaCl was applied up to a concentration of 
1.05 M, using the same system described before. The elution pattern 
is presented in Fig. 2-5. Fraction Ic was roto-evaporated and desalted 
USing a column of Sephadex G 15. After roto-evaporation and freeze-
drying the weight of fraction Ic was 1.12 g. Thin layer 
chromatography On cellulose plates revealed a single spot and the 
N-terminal amino acid was glycine. This fraction consisted of 
melittin. 
The diagram below summarizes the purification of peptide 
.401 and melittin. 
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CHAPTER 3 
PEPTIDE 401 AND INHIBITION OF PROSTAGLANDIN SYNTHESIS 
3-1 Introduction 
In this introduction, prostaglandins in general will be 
reviewed briefly, with more emphasis given to prostaglandin E2, since 
the experiments described in this chapter are mostly concerned with the 
participation of this prostaglandin in the inflammatory process. 
3-1-1 Isolation and structure of prostaglandins 
The prostaglandins, discovered and described by Von Euler (55) 
and independently by Goldblatt (74), are poly unsaturated, cyclic, hydroxy 
fatty acids (although C-19 fatty acids can generate prostaglandins, the 
most common percursors are the C-20 fatty acids). The following diagram 
shows the main prostaglandins together with their precursors. The 
structure of prostaglandins is based on that of prostanoic aCid. The 
subscript numerals denote the number of unsaturated bonds. Prostaglandins 
are divided into two main groups, namely E and F. The E series is 
characterized by the ketone. group at C-9 and is thus named because during 
the isolation procedures, it was found to be more soluble in the ether 
phase, while the prostaglandins F, with an hydroxyl group at C-9, were 
more soluble in the phosphate buffer phase (25, 24). Prostaglandins A 
and B can be obtained by alkaline treatment of prostaglandins E, and both 
occur naturally. Thus it is believed that the A and B compounds are 
probably derived from prostaglandins E by dehydration reactions occurring 
in vivo, but whether they ŸÙVŮŨŠXĚwell defined physiological actions or 
are simply catabolic products of PGE's is not certain (65). It has been 
+ 
suggested, however, that PGA2 may be involved in the .control of Na 
excretion (108). 
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3-1-2 Physiological actions and occurrence of PGs 
Prostaglandins have been demonstrated to participate in a 
number of different biological processes such as contraction of 
gastrointestinal smooth muscle (22), inhibition of gastric secretion 
(139), contraction of reproductive smooth muscle (54, 93), relaxation of 
respiratory smooth muscle (113), effects on the cardiovascular system 
(92), blood platelet aggregation (102), diuresis and natriuresis (172, 
108), luteolysis (134), actions on the nervous system (91), intraocular 
. 
pressure (179), adipose tissue (165) and the endocrine system (90). 
Prostaglandins were shown to be present in almost all 
mammalian tissues (97, 98), in corals (185) and in insects (46). 
However, the amount of prostaglandins which can be isolated from each 
tissue varies, and usually the human seminal fluid and seminal vesicles 
are the richest sources of prostaglandins (80, 32, 50). Because of 
their widespread occurrence and functional diversity, it has proven 
difficult to ascribe a specific physiological role to the prostaglandins. 
The accepted idea is· that prostaglandins are modulators of hormone 
activity since many of the physiological actions of prostaglandins appear 
to be mediated through the adenyl and guanyl cyclase systems (89, 138, 
200). The intracellular concentrations of cyclic AMP and GMP seem to 
be the controlling factors for the release of pro-inflammatory agents 
such as histamine and lysosomal enzymes (94). In some cases, however, 
prostaglandins can also be considered as hormones in the classical sense,· 
Since they can be released into the circulation and affect target cells 
distant from the site of release. This was observed with PGA's and 
. ÖŇŃÎŸĦĚ PGE's are usually' catabolized very quickly (62, 173). 
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3-1-3 Precursors of prostaglandins 
The essential fatty acids which are the precursors of 
\ 
prostaglandins do not seem to be available in a free form in the serum. 
It is believed that the major sources of arachidonic acid and 
dihomolynolenic acid are the phospholipids associated with the cell 
membranes (106). It is assumed that phospholipases play an important 
role in providing the substrates for the prostaglandin synthetases (103). 
The results of Bartels et ale (17) showed that injection of phospholipase 
A into intestines of frogs led to formation of prostaglandins, probably 
due to an increased amount of available precursors. 
3-1-4 Biosynthesis of prostaglandins 
The enzymatic complex, responsible for the synthesis of 
prostaglandins, generically called prostaglandin synthetase 
Ll.14.99.l - 8,11,14 - eicosatrienoate, hydrogen donor: oxygen oxido-
reductase - in the case of PGEl synthesis, when 8,11,14 eicosatrienoic 
acid is the precursoi/, is also present in most of the tissues 
investigated (88, 137). 
Prostaglandin E2 was found to be formed by enzymatic 
cyclization of arachidonic acid (20, 51). The results ŸȚĚstudies on 
the mechanism of biosynthesis of prostaglandin E2 (101, 125, 144, 147), 
are summarized below. There is no reason, however, to believe that the 
biosynthetic pathway of the other prostaglandins is very different 
from that of PGE2 (19). 
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These in vitro studies on the mechanism of synthesis of prostaglandins 
showed that PGE2 and ÖŇŃÎŸĚwere not interconvertible although it is 
possible that in vivo theRe are enzymes which can reduce PGEl and PGE2 
to ÖŇŃÍŸĚ and PGF2o(. respectively. 
Details regarding the factors regulating which specific 
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prostaglandin is to be formed by the enzymatic complex are not completely 
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understood. In the work of Lands, et al. (104) it was found that 
glutathione, one of the cofactors used for the in vitro studies of the 
prostaglandin synthetase, favoured the formation of PGE's, whereas the 
presence of copper prevented the formation of PGE's and allowed reduction 
of the intermediate endoperoxide to form PGF's. 
Prostaglandin synthetase from sheep seminal vesicles has been 
partially purified (148, 149). It was found to be insoluble and 
associated with the microsomal fraction., Experiments in vitro 
demonstrated that the enzymatic complex requires glutathione and 
hydroquinone or adrenaline as cofactors (52). During the isolation 
procedure it was found that a heat stable soluble cofactor was necessary 
for activity. This heat stable cofactor presumably plays the same role 
as the cofactors added to the medium in the in vitro experiments (149). 
3-1-5 Fate and release of prostaglandins 
Once formed prostaglandins seem to be catabolized very quickly 
by a prostaglandin dehydrogenase. Prostaglandin dehydrogenase is present 
in practically all tissues investigated, but the lungs are considered to 
have the highest activity (6, 150). Until quite recently it was assumed 
that prostaglandins were not stored in the cells, but synthetized and 
released at the time of stimulUS (135) since the amount of prostaglandins 
which could be extracted from the 'resting' tissues investigated was 
always very small. However, a recent paper suggests that prostaglandins 
can be stored in adipose tissue (110) and that corticosteroids are able 
to inhibit their release but not their synthesis. The results of Higgs 
and Youlten (87) showed that 'resting' rabbit ŮŬŨXÜŬŲŮUŬŪŸȘŨŤŬȘXWŤVĚ
'contain some amount of stored prostaglandins, although this could be 
reflecting some biosynthesis of prostaglandins. The control of 
prostaglandin synthesis is ·so far not yet understood. The release of 
prostaglandins from the tissues appears to occur following mechanical, 
hormonal and neurological stimuli (135). 
3-1-6 Prostaglandins in the inflammatory process 
Of all the reported biological actions of prostaglandins, 
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their participation as mediators of the inflammatory process, is one of 
the most well documented. Although there is plenty of evidence available 
demonstrating direct and indirect effects of prostaglandins in 
inflammatory states, the mode of action of these compounds is not yet 
clear. This situation is made even more complicated since in many cases 
the same prostaglandins can have antagonistic effects and the amount and 
type of prostaglandins present in an inflammatory exudate depends On the 
kind of inflammatory model used, and on the species being studied (200, 
166). For example there are some models of experimental adjuvant 
.polyarthritis where PGEl and PGE2 were shown to have anti-arthritic 
activities in the rat (10, 203). These prostaglandins were also able to 
reduce the levels of lysosomal enzymes such as j!-glucuronidases (201) 
and to inhibit phagocytosis by guinea pig polymorphonucleocytes (39). 
These effects would seem to confer to the prostaglandins of the E series, 
anti-inflammatory activities. However, in most models of acute 
inflammation, prostaglandins or the E series were shown to act as potent 
pro-inflammatory agents, causing erythema, oedema,increased vascular 
permeability and pain, whereas prostaglandins of the F series were 
generally anti-inflammatory, especially ÖŇŃÎŸĚ (41, 69, 196, 176). The 
reason for such conflicting results is not clear, but certainly predictable 
·on the basis of the multiplicity of functions of prostaglandins, on their 
widespread occurrence, as.well as the apparent non-specificity of stimulus 
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required for their synthesis and release. Another point to consider 
is the different nature of the inflammatory models employed in these 
studies. An adjuvant arthritis condition must differ considerably from 
the acute carrageenan oedema, whether considering the cellular aspects 
(in chronic inflammatory states, there is ŸĚbig proportion of monocytes 
circulating while in the more acute cases such as the carrageenan oedema, 
polymorphonucleocytes predominate in the early stages) (188), or the ' 
general chemical environment, that is, the participation of different 
components in the two different models which could act as blockers or 
potentiators for prostaglandin action. The local concentration of 
prostaglandins also appears to be an important factor determining their 
final effect on the inflammatory state. In the adjuvant arthritis 
experiments, where PGEl and PGE2 were found to be anti-inflammatory 
relatively high concentrations (200-500 ŸŦĚper rat injected at each 
time) were used, which produced side effects such as somnolence and 
occasional diarrhoea (10, 203). The results of Glenn et ale (72, 73) 
showed that PGEl and PGE2 were able to produce inflammatory oedemas in 
rats, mice, gerbils and' hamsters when injected into these animals. 
When PGEl was injected locally into croton oil induced granulomas, it 
had a potent pro-inflammatory effect; but higher dosages of this, 
prostaglandin (0.5 - 4 mg/kg) inhibited the granulomatous reaction. 
Again such pharmacological doses which were required to produce anti-
inflammatory and anti-arthritic effects caused adrenal hyperplasia, 
u 
prostration and diarrhoea. Another instance of the dose dependent 
action of prostaglandins is the lymphocyte transformation. Lymphocyte 
transformation into blast cells is inhibited by several prostaglandins 
(162, 163), but higher concentrations of PGEl are able to stimulate 
lymphoblast transformation (189). 
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Dose dependent biphasic effects are known to occur with other 
mediators of the inflammatory process. Histamine, which is responsible 
for the early stages of the acute inflammation is also able to inhibit 
further release of histamine from mast cells when its concentration rises 
to a certain level (30). The idea that prostaglandins can antagonize 
their own actions depending on the concentration is likewise compatible 
with a ffeed-back' control with the purpose of avoiding perpetuation 
of the inflammatory condition. 
Prostaglandins are .able to reproduce many of the observed 
manifestations associated with inflammation. Vasodilatation was 
observed in the frog by Von Euler (55). Peripheral vasodilatation was 
obtained in man when prostaglandins were injected intravenously (21). 
Intradermal injections of PGEl ŠŸTĚPGE2 caused oedema and erythema 
(3, 4). Prostaglandins induced local increased vascular permeability 
in the rat and man (42, 96) and potentiated the actions of histamine 
. . 
and bradykinin in increasing local vascular permea9ility (192, 59) 
and increase in arterial pressure (61). Prostaglandins, mainly PGE2, 
were isolated from inflammatory exudates in rat and in man (41, 8, 194, 
193) and appear to be released during the so-called second phase of 
inflammation or the 'prostaglandin phase' (48, 49). This release Of 
prostaglandins in the carrageenan oedema was correlated with leucocyte 
migration to the site of inflammation (48, 49, 5), but whether the 
invading leucocytes were responsible for the synthesis and release of 
the prostaglandins was not certain (175), since there are cases when 
prostaglandins are released locally during the inflammatory stimulus 
and are able to induce increased vascular permeability in the absence 
of polymorphonucleocytes (195). However, it is known that rabbit 
polymorphonucleocytes are able to synthetize prostaglandins, mainly 
PGE1 and that this synthesis can be stimulated during phagocytosis of 
bacteria (87, 86). It was suggested that the phospholipases of the 
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leucocytes, which are normally stored in the lysosomes, are released 
during the endocytosis of carrageenan, which WUŤŸHĚ by acting on the 
phospholipids of the membranes provide the' precursors f?r the synthesis 
of prostaglandins (5). This suggestion was based on the observation 
that other lysosomal enzymes such as fl -glucuronidase and acid 
phosphatas·e are released concomitantly with the prostaglandins in the 
carrageenan oedema. 
Prostaglandins El and E2 were shown to have chemotactic 
activities for leucocytes (95, 116) which led to the suggestion that 
this effect could be part of a physiological mechanism of attraction of 
leucocytes to. the site of inflammation for as long as phagocytosis was 
occurring (86, .115). Su.ch a process, in an uncontrollable way, could 
be occurring in autoaggressive pathological states such as rheumatoid 
arthritis (86). In chronic states of inflammation, the participation 
of PGEI was also associated with stimulation of collagen biosynthesis 
and thus abscess formation (7, 28). 
In a recent report (29) the carrageenan oedema was induced 
in rats lacking the dietary essential fatty acids, which are the 
precursors of prostaglandins. It was found that the rat paws did not 
swell as much as the controls, but that arachidonic acid restored the 
swelling to the control levels. In these animals, the kinin phase of 
the carrageenan oedema is unaltered. Interestingly enough, if the 
oedema is induced with chicken egg white, instead of carrageenan, no 
difference in the swelling of paws can be observed between the essential 
fatty acid deficient rats and controls, showing once more the different 
characteristics of different inflammatory models. 
-- --------------
Prostaglandins El and E2 are able to produce fever when 
injected directly in the brains of cats and rabbits (117, 57) and have 
also been shown to be associated with pain, acting directly at nerve 
endings (59) and possibly potentiating the effects of ,bradykinin and 
histamine (63). 
3-1-7 Inhibition of PG synthesis by anti-inflammatory agents 
Recently, strong support to the idea that prostaglandins are 
mediators of the secondary phase of the inflammatory process was given 
by the results of Vane et al o (174, 161, 60), which showed that non 
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steroidal anti-inflammatory agents such as aspirin and indomethacin are 
. ŸĚ . . ŸĚ . 
inhibitors of prostaglandin synthesis in vitro and in vivo. These 
inhibitors do not interfere with the early development of the carrageenan 
oedema in the rat, which is believed to be mediated by histamine, 
serotonin and bradykinin ĜÏĲĞŸĚ In vivo experiments showed that the 
observed anti-inflammatory activity of these non steroidal compounds 
occurred mainly during the prostaglandin phase of the carrageenan ŬŤTŤÜŸĚ
and that the non steroidal anti-inflammatory agents were also able to 
inhibit migration of monocytes to the site of inflammation (49). 
The following in vitro experiments were carried out in order 
to establish if the anti-inflammatory activity of peptide 4?1 could in 
any way be c'orrelated with inhibition of PGE2 synthesis, using an 
enzymatic complex obtained from sheep seminal vesicles. 
" 
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3-2 Experimental 
3-2-1 Materials 
The two batches of the prostaglandin synthetase complex used 
were obtained from sheep seminal vesicles and were gifts from Dr. D. 
Wallach (The Upjohn Co.) and Dr. R.J. Flower (The Wel1come Research 
Laboratories). Arachidonic acid, glutathione (reduced) and trizma 
base were purchased from Sigma Chemical Co.; L-epinephrine from Koch-
ŸÙŦUWĚLaboratories; acetyl salicylic acid from Aldrich Chemical Co.; 
arachidonic-l-14C (58 mci/mM) from the Radiochemical Centre, Amershamj 
silica gel plastic backed thin layer plates from Merck. Indomethacin 
was a gift from Dr. J. Hanson (The Kennedy Institute) and PGE2 in 
crystalline form from Dr. J.E. Pike (The Upjohn Co.). 
All the chemica1swere'used with no further purification. 
The labelled and unlabelled arachidonic acid were checked for purity 
by applying them onto a silica gel thin layer plate which was developed 
in a solvent system consisting of ethyl acetate : water trimethy1 
pentane : ac'etic acid (11 : 10 : 5 : 2 v/v'.· The front was allowed to 
run for 17 cm and the plate ŴŸVĚstained under iodine vapour, presenting 
no signs of impurities. 
Spectrophotometric assay of prostaglandin synthesis 
The first spectrophotometric assay tried was that of 
Takegushi et a1. ŸÍĬİĞĦĚ This method consisted in measuring the formation 
of adrenochrome during the incubation of the enzymatic system with 
o 
arachidonic acid and adrenaline in tris buffer pH 8.3 at 30 C. 
;," 
Adrenochrome is an ŬẄÙTŠWŸẂŤĚproduct of adrenaline (L-epinephrine). The 
ŬẄÙTŸWÙŬŪĚof adrenaline takes place at the same time as arachidonic acid 
undergoes the oxidative cyc1ization to form PGE2• The following sequence 
of reactions is believed to occur: 
ÕŸÕÑĚ
ÕŸÔĞĚ
I 
CH3 
adre nochrom e 
The adrenochrome formed is then estimated by spectrophotometry since 
it absorbs light at 480 mIL. The results however were not satisfactory, 
probably due to the instability of adrenochrome in the alkaline pH of 
the incubation medium. In this alkaline pH, adrenochrome oxidises 
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forming melanin, a brown pigment with a different absorption maximum (83). 
As the results obtained by incubation of the enzymatic system with known 
inhibitors of prostaglandin synthesis, such as aspirin and indomethacin, 
were not in agreement with the results reported in the literature, and 
as there was much variation within a single set of experiments, this 
method was abandoned. 
3-2-3 PGB2 method 
This method is based on the alkaline conversion of PGE2 to 
PGB2• When prostaglandins of the E series are incubated in an alkaline 
medium, the so called PGB's are formed which absorb ultraviolet light 
at 278 mil (18). 
, 
OK 
The sequence of reactions involved is the following: 
ĤŚŸĞĚin the presence 
of weaJ.<: acid or 
base 
ĒŸÕÕÑĚ
Lt6 
PGA2 (absorption max.217 nm) 
rearraneemen ŸŪĚ
of stron,'; alkali 
PGB 2 (absorption max_ 278 run) 
e presence 
The experimental procedure, based on the method of Wallach at ale (181), 
consisted in incubating 10 mg of the acetone-pentane powder containing 
the prostaglandin synthetase with 0.273 mM arachidonic acid, 3.6 mM 
o 
adrenaline in 0.05 MTris buffer pH 8.3 for 5 min at 30 C with constant 
agitation. The final volume of the incubation medium was 3 ml. 
Arachidonic acid, which was kept in a stock benzene solution (50 mg / 
10 ml), was added to a 10 ml volumetric flask and the benzene was 
evaporated under a stream of N2- The reaction started with the addition 
of the incubation medium containing the enzymatic complex to the flask 
containing the dried arachidonic acid, and after 5 min it was stopped 
by adding 0.25 ml of 2 M citric acid. The inhibitors tested were usually 
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pre-incubated with the enzymatic suspension for 5 min before the 
reaction started. Indomethacin, which is not soluble in aqueous 
solutions, was dissolved in a few drops of ŤWUŸŪŬŨĚ (absolute) and then 
the but.fer was added to the required volume. It was found that the 
small amount of ethanol in the incubation medium did not interfere in 
any way with the activity of the enzyme. The three blanks consisted 
of pre-incubating the enzyme with citric acid before adding it to the 
substrate flask, incubating the enzymatic complex in the absence of 
o 
arachidonic acid and pre-heating the enzyme at 60 C for 5 min, cooling 
it to 30°C and then incubating it in the normal way. 
Immediately after the reaction was stopped, the incubation 
medium was transferred to a 100 ml separating funnel and the prostaglandins 
were directly extracted with 20 ml of dichloromethane. The lower phase 
was collected in a 100 ÜŸĚpear-shaped flask and the remaining upper 
phase was transferred to another separating funnel in order to obtain 
more of the dichlorom'ethane extract. 
The extract thus obtained was dried ẀŪŸŤŲĚvacuum, using a roto 
evaporator and the residue diluted in 3 ml of methanol (sol. A). From 
solution A, an aliquot of 1 ml was further diluted with 3 ml of methanol 
and the absorbancy at 278 ÜŸĚwas measured using a Unicam SP 500 
spectrophotometer. Another 1 ml aliquot from solution A was incubated 
with 0.2 ml of a 3 M methanolic solution of KOH, diluted to a total 
volume of 4 ml with methanol and incubated at 50oCfor 30 min, to convert 
all the PGEZ formed during the enzymatic incubation into PGB2• Atter 
the alkaline treatment, the absorbancy of this solution was measured at 
278 ÜŸHĚ and the amount of chromophore formed under alkali treatment is 
given by the difference between the two readings. This value was then 
used to calculate the original concentration of PGEZ' using a standard 
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concentration-absorbancy (278 ÜŸĞĚ curve for known amounts of PGE2 
which had been subjected to the alkali treatment. 
Radiochemical method 
This method was conducted essentially as described by Flower 
et ale (66). The enzymatic complex used in this set of experiments 
came from another batch, but was also obtained from sheep seminal 
vesicles. 
The enzymatic complex was incubated at a concentration of 
4 mg/ml, for 10 min at 370 C with constant shaking, in a medium containing 
14 1 mM arachidonic acid (0.08 ŸȘÙĚof 1- C-arachidonic acid was added to 
the benzene solution of the cold arachidonic acid and the solvent was 
removed by evaporation under N2 ), 5 mM reduced glutathione and 5 roM 
adrenaline, in a 100 roM Tris buffer solution, pH 8.2. The total volume 
of the incubation medium was 0.5 mI. The inhibitors were incubated with 
the enzymatic suspension for 5 min prior to their addition to the 
( 
substrate. The blanks consisted of incubating the enzymatic complex 
with 0.25 ml of lN HCl prior to addition to the substrate. 
The reaction was stopped by addition of 0.25 ml of lN Hel and 
then the prostaglandins were extracted with 1.5 m1 of ethyl acetate. 
During extraction, the tubes were stirred for 15 seconds on a Vortex 
mixer and a1iquots of 1 m1 were collected from the upper phase. These 
aliquots were taken to dryness under vacuum and the residues were 
redissolved in 0.05 ml ot ethanol (absolute). From these solutions, 
aliquots of 0.02 ml were applied to the plastic backed silica gel plates 
using automatic pipettes, and the plates were then developed in a 
solvent system conSisting of the upper phase of the following ÜÙẄWẀŲŸJĚ
ethyl acetate : water : trimethylpentane : acetic acid (11 : 10 : 5 : 2 
ĤĤĤĤĤĤĤŸĤĤĤĤĤĤ
v/v). Samples of PGE2 were also applied as standards. The front was 
allowed to run for 17 em and then the plates were dried at room 
temperature. Prostaglandins were visualized by exposing the plates 
to iodine vapour and the spots corresponding to PGE2 were cut and' 
placed directly in scintillation vials, containing 10 ml of a solution 
of 4 g of 2,5-diphenylaxazole (DPO) in 1000 ml of toluene and 500 ml 
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of the detergent Triton X-lOa. The vials were stirred, and then counted 
in a Beckman liquid scintillation spectrometer. Before every 
. 
experiment, the vials containing the scintillation fluid were counted 
and the values obtained used as the radioactive background. 
In the first experiments, the spots corresponding to ÖŇŃÎŸĚ
and PGD2 were also cut and counted, but as the inhibition found for a 
given concentration of peptide 401 was constant for the prostaglandins 
and D2, in some experiments only PGE2 samples were counted. 
ŸĤĤĤĤŸĤĤĤĤĤĤĤĤĤĤĤĤĤĤĒĶĚ
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3-3 Results 
. 3-3-1 Spectrophotometric method (PGB2 method) 
Table 3-I shows the results of submitting standard samples of 
known FGE2 concentration to the alkali treatment described before. 
This gives the straight line calibration, shown in Fig. 3-1, the 
equation of the straight line being 
y = 0.1702 + 14.659 x 
where y = PGEZ concentration ĜŸŦIÜÍĞĚ
x = difference between absorbancies before and after alkali 
treatment. 
This equation was used to calculate unknown FGEZ concentrations. 
Table 3-I 
Standard concentration-absorbance (278 nm) 
curve for PGEZ treated with alkali 
PGE2 concentration 
(ug/m1) 
16 
8 
2 
Absorbance 278 nm 
Average 
10083} - 1.103 x = 
1.124 
.556 } 
=.557 x 
.558 
0286} -=.287 x 
.289 
.147) -x =.146 
.146 
...-
&.n 
1 
E 
ŸŨĪĚ
N 
ci 
o. 
.2 
• 
0'" 
FiG 3-1 Standard concentration-absorbance(278nm) 
curve for PGE2 treated with alkali 
(da ta from table 3-I) 
ŸĦĚ
/' 
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When samples of PGE2 of known concentrations were added to a phosphate 
buffered saline, pH 704, extracted with dichloromethane and subjected 
to the same alkali treatment as described before, the recovery of the 
prostaglandin E2 was of the order of ĨŨĘŸĚ207%. 
The results of the experiments where peptide 401, indomethaCin 
and aspirin were incubated with the prostaglandin synthetase complex, 
are summarized in Table 3-11 and Fig. 3-2. 
Although other prostaglandins which are also products of the 
enzymatic reaction can absorb ultraviolet light at 278 nm upon alkali 
treatment (18, 23), in the experiments employing the spectrophotometric 
method described before, no attempt was made to separate the extracted 
prostaglandins formed during incubation of the enzymatic complex with 
arachidonic acid. This is probably the reason why the values obtained 
employing the spectrophotometric method are higher than the ones obtained 
using the radiochemical method. However, it has been demonstrated that 
under the conditions used in the above experiments (arachidonic acid 
concentration of 0.273 mM), PGE2 is the main product of the enzymatic 
reaction (66). Peptide 401, incubated with the enzymatic complex at a 
concentration of 0.6 mg/ml is able to inhibit PGE2 formation by 41%. 
A concentration of peptide 401 of 0.06 mg/ml fails to show any 
significant inhibition of PGE2 synthesis. Indomethacin (20 ŸÓĞĚ and 
aspirin (1 mM) produced inhibitions of 71% and İĨÖŸĚrespectively. 
3-3-2 Radiochemical method 
14 The counting efficiency of 1- C arachidonic'acid was of 85%, 
with the scintillation fluid containing Triton X-100. Fig. 3-3 shows 
the quenching curve obtained by plotting the counting efficiency of 
. . 
14 1- C-arachidonic aCid, against the external standard ratio of the 
ŸŦGÖŇNÎĚin 
3 ml of 
extract 
Mean AN S.D. 
_._- --
Table 3-II 
.,) 
Effect of peptide 401, indomethacin and aspirin on PGE2 synthesis 
ĿŬŪWŲŬŸĚ 401 401 (22.8 ŸÓĚ (228 J.l.M 
0.06 mg/ml) 0.6 mg/ml) 
10.08 9.33 6.62 
10.44 9.12. 5.91 
9.12 8.46 5.34 
ĲĦÎŸĚ 7.89 4.95 
9.99 ŸÌĦÌĮĚ 6.33 
o .X . 09.76+0 .. 57 - 8.97!,0.83 ·x 5.83+0.68 
-I -( 
o Enzyme ŸŲŤĤUŤŠWŤTĚat 60 C for 5 min 0 
Enzyme incubated without arachidonic acid 
Indomethacin 
(20 ŸÓĞĚ
2.34 
3.78 
3.12 
2.79 
_0 .2.61 
2.92!,0.55-
PGE2 (Ug in 3 m1) 
0.39 
0.272 
Aspirin 
(1 I!lH) 
2.46 
ŸĦĮĲĚ
1.23 
3.06 
1.74 
5.73 
Z.68!,1.61 
CoS, 
W 
FI G ĨŸÎĚ - Effect of peptide 401, indomethacin and 
aspirin on PGE2 synthesis. (.data. from Table 3-11) 
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FIG 3-3 - Quenching curve for 1- C-Arachidonic acid. 
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Beckman spectrometer. Quenching was obtained by stepwise addition of 
chloroform to a sample of known activity. 
In order to calculate the amount of prostaglandin E2 formed 
in the enzymatic reaction, several dilutions of a known concentration 
of 1_14C_arachidonic acid were made in ethanol and aliquots of these 
dilutions were counted in the liquid scintillation spectrometer. 'These 
results are presented in Table 3-III and Fig. 3-4. The figures on the 
extreme right mean the amount of PGE2 which would be formed from the 
dilutions of arachidonic aCid, assuming total conversion of the 
arachidonic aCid. 
Table 3-III 
Correlation between several dilutions of known 
activities of 14 1- C-arachidonic acid and DPM 
.... - ...... 
DPM J.1g arach. acid J.1€; PGE2 
42670 0.101 0.116 
20740 0.049 0.0558 
11090 0.0262 0.0298 
5630 0.0133 0.0151 
2680 0.00634 0.00722 
each value represents the average of.two-,determinations 
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The least square straight line in Fig. 3-4 is represented by the equation 
y = 104.654 + 367482.74x 
where 
ŸŬĚ
.-
)( 
ŸĚ
a. 
0 
0 
FI G 3-4 - Standn.rd concentration-DPM curve for 
PGE2 (data. from Table 3-III) 
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The equation used to calculato unknown concentrations of 
PGE2 had to be modified to allow for dilution of the sample during tho 
experimental procedure and for extraction losses. The dilution factor 
multiplied by the extraction factor was 4.38, giving a final equation: 
4.38 y = 104.654 + 367482.74 x and this equation was used to 
., 
calculate PGE2 concentrations in the ȚŬŨŨŬŴÙŸŦĚexperiments. The 
extraction factor was determined by applying a known amount of arachidonic 
acid to the silica gel plates, developing it and then counting the spot 
corresponding to arachidonic acid, as done during the experimental 
ŮŲŬȘŸTẀŲŤĦĚ
The results of the experiments where the prostaglandin 
synthetase was incubated with several concentrations ot peptide 401 and 
with 40 IlM indomethacin and 1 mM asplrin, are presented in Table 3-IV 
and Fig. 3-5. 
Table 3-IV 
Effect of peptide 401 on prostaglandin synthesis 
-' . 
, 
Control 0.0144 ÌŸÍÌĲĚ
401 (1 mg/ml = 380 jlM) 0.00035 0.012 
401 (0.5 mg/ml = 190 11M) 0.0023 0.063 
401 (0.25 mg/ml =95 uM) 0.0087 0.111 
401 (0.05 mg/m1 = 19 IlM) 0.0113 0.114 
, '-401 (0.025 mg/ml = 9.5 1111) 0.01 0.097 
0.01 
0.001 
0.0044 
0.0092 
0.'011 
0.013 
0.0148 
0.0027 
0.005 
0.0004 
401 (0.005 mg/ml = 1.9 uM) 0.014 0.0998 
IndomethaCin (40 UM) 0.003 . 0.011 
. Aspirin (1 mM) 0.072 ÌĦÌŸĮĚ
Blank 0 0.00008 
each value represents the averago of .two determinations 
.' 
FIG 3-5 - Effect of peptide 401 onPGE2 synthesis. (data from Table 3-IV) 
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Peptide 401 is able to inhibit PGE2 formation by ÏŸĚat a 
concentration of 0.5 mg/ml. Smaller concentrations of peptide 401 
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fail to show any significant effect on PGE2 synthesis although peptide 
401 is able to inhibit PGF2o<. synthesis at a concentration of 0.25 mg/ml 
(see Table 3-IV and Fig. 3-6). 
The results of the experiments where peptide 401 was incubated 
in a narrower range of ȘŬŪȘŤŪŸŲŠWÙŬŪVĚare presented in Table 3-V and 
Fig. 3-7. In Table 3-V, the results of experiments where melittin, 
another basic peptide isolated from bee venom (see Chapter 2), was 
incubated with the prostaglandin synthetase complex are also presented. 
Table 3-V 
Effect of peptide 401 and melittin on PGE2 synthesis 
Jlg PGE2 
Control 0.072 
401 (1 mg/m1) 0.0114 
. 
401 (0.75 mg/m1) 0.0149 
401 (0.5 mg/m1) 0.043 
401 (0.4 mg/m1) 0.058 
401 (0.3 mg/m1). 0.077 
Me1ittin (0.5 mg/m1) 0.115 
Blank. 0.000263 
.I 
each·va1ue is the average of two determinations 
This was done in order to determine if the inhibition found with peptide 
. , 
FIG 3·6_ Effect of peptide 401 on PGF2O' and PGD2 synthesis (data from Table 3-IV) 
-ŸĚ
-N 
0 
l!) 
a.. 
"0 
C 
Ilt 
-<:> 
-'i 
N 
lL.. 7 l!) 
a.. 
01 
c 
-"t 
5 
1 
.05 .25 .5 
0 1 401 mgt ml 
, 
.. 
t 
\ 
"- , 
N 
10 
-)( 
N 
W 
(!) 
0.. 
0'1 
, . :l. 
o 
• 
FI G 3-7 - Effect of peptide 401 on PGE., synthesis 
(data from Table'3-V) ŸĚ
'\ 6 . 
5 
4 
3 
' .... ', 
2 
1 -. 
.3 .4 .5 1 
401 mg/ml 
• 
G2 
. , 
i' 
I 
1 
63 
activate the formation of PGE2• However this effect may have been 
reflecting a partial solubilization of the enzymatic complex, as a 
consequence of the detergent-like properties of melittin (154). In 
the above experiments only the spots corresponding to PGE2 were collected 
and counted. It can be seen that peptide 401 ÙŪUÙŞÙWÙŬŸĚof PGE2 
formation occurs down to a concentration of 0.4 mg/ml. Although the 
absolute values varied from one experiment to another, the inhibition 
caused by peptide 401, reflected as the ratio between the controls and 
a given concentration of peptide 401, was constant and reproducible in 
all experiments considered (1.63 .:!:. 0.13 for 0.5 mg/ml 401). 
In order to test the hypothesis that melittin was activating 
the synthesis of PGE2 ,through partial VŬŸẀŞÙŨÙYŠWÙŬŪĚof the enzyme, 
Triton X 106, a detergent, was incubated with the PG synthetase at a 
concentration of 0.4% (v/v). These results are presented in Table 3-VII, 
and it can be seen that there is only a slight difference between the 
Triton X-IOO group and the controls. 
When peptide 401, at a concentration of 0.5mg/ml, is incubated 
,with 3 mg of the PG synthetase, the ratio between controls and 401 groups 
was 1.82. The results are presented in Table 3-VI. The inhibition of 
, ' 
401 is more pronounced in the presence of 3 mg of the enzymatic complex, 
instead of the usual Z mg per tube of the previous experiments. 
Table 3-VI 
Effect of peptide 401 on PGEZ synthesis when 
incubated with 3 mg of the enzymatic complex 
Control 
401 (0.5 mg/ml) 
0.35 
0.192 
.. 
Although the opposite effect would be expected, the limited amount of 
the enzymatic complex did not allow tests using different amounts of 
the enzymatic complex, incubated with a constant amount of 401 and 
arachidonic acid. The ratio between the controls and 401 groups was 
not very far from the ratio obtained in exPeriments where 2 mg of the 
enzymatic complex were incubated with peptide 401 and it is not 
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therefore possible to draw conclusions about the direct action of peptide 
on the enzymatic complex. 
• 
The results of experiments where fixed amounts of peptide 401 
were incubated with the enzymatic complex and varying concentrations 
of arachidonic acid, are presented in Table 3-VII and Figs 3-8 and 3-9. 
Table 3-VII shows also the.results of incubation of the enzymatic 
complex with a 0.4% (v/v) solution of Triton X-100, at a substrate 
concentration of 1 mM. 
Table 3-VII 
Effect of peptide 401 on prostaglandin synthesis 
at several substrate concentrations 
CONTROL 401 (0.5 mg/ml) 
ŸŦĚPGF2 
Arach.ACid 
0.1 mM 0.000585 
0.5 mM 0.00383 
1mM 0.0165 
2mM 0.027 
Triton X-I00 (0.4%) 
l'mM arachidonic acid 
Jlg PGE2 ug PGD2 
0.0356 0.00051 
0.122 0.0054 
0.114 0.0124 
.0.071 0.028 .. -
Jlg PGF2 
0.0055 
ug PGF2 ŸŦĚPGE2 
0.000323 0.028 
0.0021 - 0.056 
0.007 0.077 
0.025 0.129 
0.121 0.008 
-each value ·is the average .ot two determinations 
Jlg PGD2 
0.00022 
0.0022 
0.0076 
0.029 
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FIG 3·8 -Effeot of peptide 401 on PGE2 synthesis at 
several substrate oonoentrat1ons.(data from 
Table 3-V11) 
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FIG 3-9 - Effect of peptide 401 on PGF2 and PGD2 
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It can be seen that the inhibition caused by peptide 401 on 
the synthesis of PGE2 , ÖŇŃÎŸĚ and PGD2 is dependent on the substrate 
concentration. Inhibition by peptide 401 (0.5 mg/ml) is observed up to 
67 
a substrate concentration of 1 mM. The inhibition of PGE2 formation found 
when the substrate concentration was increased, is in agreement with the 
results of Flower et a1. (66). However, due to the insoluble character 
. of both arachidonic acid and the enzymatic complex, this effect is 
difficult to interpret. It should also be kept in mind that the usage 
Of' the term 'concentration' is not strictly correct under these 
circumstances. The interaction between arachidonic acid and the 
enzymatic system must be similar to the known complex formation which 
occurs between long chain fatty acids and proteins present in the serum 
(especially albumin). The insolubility of the prostaglandin synthetase 
complex in aqueous soluti?ns must be reflecting a highly hydrophobic 
structure which presumably favours even more the interaction with 
arachidonic aCid. 
In these conditions (of increased substrate 'concentration') 
other products of the enzymatic reaction are being formed at higher 
rates than at lower substrate concentration. It is not known however, 
what controls these mechanisms and possibly the activation of PGE2 
formation induced by peptide 401 at substrate concentrations of 2 mM 
(see Fig. 3-8), could be a consequence of an inhibitory action of peptide 
401 on the synthesis of prostaglandins other than PGE2• The inhibition 
caused by peptide 401 was not so pronounced in the case of PGF 20< and 
PGDz formation (Fig. 3-9). 
These results indicate also that some complexing between 
peptide 401 and arachidonic acid could be occurring. Such a complexing 
would be favoured by the opposite charges of those two compounds at the 
pH of the incubation medium, although it can be seen in Table 3-V that 
melittin, which is more basic than 401, did not show any inhibition of 
prostaglandin synthesis but instead an activation. 
3-3-3 Tests for complex formation between peptide 401 and 
arachidonic acid 
In order to test if any complexing was occurring between 
peptide 401 and arachidonic acid, which would explain the inhibition 
of prostaglandin synthesis caused by peptide 401, the following 
experiments were carried out: 
a) Peptide 401 to a concentration of 0.5 mg/ml was dissolved in the 
incubation medium (0.5 ml) and this was added to 0.1 ml of a benzene 
solution containing arachidonic acid (1 mM and with the same ratiO of 
'cold' arachidonic acid to hot arachidonic acid as used in the previous 
experiments). In the control tubes, buffer alone was incubated with the 
benzene solution of arachidonic acid. The tubes were shaken and 
incubated for 30 min at room temperature. After this incubation period, 
the WŸŞŤVĚwere centrifuged in a bench centrifuge and the upper phase, 
containing the arachidonic acid was withdrawn by means of a capillary 
tube and pipetted into another tube. The benzene was removed under a 
stream of N2 and the usual incubation medium was added to those tubes, 
followed by the enzymatic suspension. The tubes were then incubated for 
10 min at 370 C and the usual extraction procedure was carried out 
together with the thin layer chromatography. This was an attempt to 
investigate if peptide 401 would favour an increased solubility of the 
arachidonic acid in the buffer phase. The results are presented in 
Table 3-VIII. 
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Table 3-VIII 
Effect of peptide 401 on the solubility of arachidonic acid in the buffer phasE 
Control' 
Substrate pre-inc. 
with 401 (0.5 mg/ml) 
0.0378 
0.0383 
each value represents the average of two 
determinations 
This experiment shows that there was no difference between the-amount 
of arachidonic acid which could be extracted after incubation of 
arachidonic acid with peptide 401 and the buffer alone. 
b) In this experiment ÌŸÎĪĚmg and 0.5 mg of peptide 401 were each 
dissolved in 1 ml of ethanol (absolute) (to make final concentrations 
of 0.25 mg/ml and 0.5 mg/ml respectively). These solutions were added 
to tubes containing 0.05 ml of a benzene solution of arachidonic acid 
(same concentration and specific activity as in experiment ŸĞĦĚ The 
contents of the tubes were then dried and redissolved in 0.05 ml of 
ethanol. From these solutions, 0.02 ml was applied on the plastic 
backed silica gel thin layer plates and developed in a solvent system 
consisting of: n-butanol: pyridine : acetic acid : water (15 : 10 3 
: 12 v/v). The plates were stained with iodine vapour followed by 
ninhydrin, and the spots corresponding to arachidonic acid and peptide 
401 were cut and counted as described before. The results are presented 
in Table 3-IX. 
----------------;-------------,----,---
Ninhydrin 
, positive, 
spots 
Iodine 
·vapour 
positive 
spots 
Table 3-IX 
Effect of TLC solvent system on complex formation. 
between peptide 401 and arachidonic acid 
Point of application of 
sample without 401 
401 (0.25 mg/ml) 
401 (0.5 mg/ml) 
{, 
Arachidonic aCi,d (0.25mg/ml) 
Arachidonic acid (0.5 mg/ml) 
ĤĤŸŦĚ arachidonic acid 
0.00236 
0.000186 
0.000106 
0.346 
0.39 
each value represents the average of-two .. determinations 
The above results show that there was no complex formation 
between peptide 401 and arachidonic acid in the TLC conditions. 
c) Peptide 401 was dissolved in 0.05 M Tris buffer pH 8.2 to make a 
solution of 2 mg in 0.16 ml. From this solution 0.02 ml and 0.04 
ml aliquots were added to tubes containing dried arachidonic acid (same 
specific activity and amount as before) and those were incubated for 
10 min at 370 C. After incubation the tubes were dried and redissolved 
in 0.05 ml of absolute ethanol. From these solutions, aliquots of 0.02 
• ml were applied on the TLC plates and developed in the same solvent 
system as in ŤẄŮŤŲÙÜŤŪWŸĦĚ The plates were stained with iodine vapour 
and ninhydrin and the spots corresponding to peptide 401 and arachidonic 
acid were cut and counted as before. The results are presented in 
Table 3-X. 
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Table 3-X 
Complex formation between peptide 401 
and arachidonic acid in the buffer solution 
Ilg Arach. Acid 
Control 
(buffer alone 
+ arach.acid) 
401 
, 
0.25 mg 
401 0.5 mg 
Ninhydrin Positive Spot 
(at the same RF of 401) 
Iodine Vapour Positive Spot 
Ninhydrin Positive Spot 
Iodine Vapour Positive Spot 
Ninhydrin Positive Spot 
Iodine Vapour Positive Spot 
o 
0.367 
0.0019 
0.393 
0.0033 
0.35 
each value represents the average of two determinations 
d) Peptide 401 was dissolved in 0.05M Trisbuffer pH 8.2 to make a 
solution of 2 mg in 0.16 ml. From this solution an aliquot of 0.02 ml 
was added to a tube containing the dried arachidonic acid (same amount 
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and specific activity as before) plus 0.48 ml of the Tris buffer solution. 
Another aliquot of 0.04 ml, from the 401 solution was added to another 
tube containing the same amount of dry arachidonic acid plus 0.46 ml 
of the Tris buffer solution. The tubes were then stirred for 1 min on 
the Vortex mixer and then arachidonic acid was extracted in each tube 
with 1 ml of ethyl acetate. The tubes were again stirred for 15 seconds 
on the Vortex mixer and centrifuged on a bench centrifuge. The super-
natants were decanted as quantitatively as possible and transferred to 
other tubes. The extraction of arachidonic acid from the buffer phase 
ŸŠVĚrepeated once with 1 ml of ethyl acetate. Aliquots of 0.05 ml were 
then collected from the buffer phase and counted. The ethyl acetate 
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phase was dried and the residue redissolved in 0.5 ml of absolute 
ethanol. From this solution aliquots of 0.05 ml were collected for 
counting. The results are pres'ented in Table 3-XI. 
Buffer phase 
Table 3-XI 
Effect of peptide 401 on the solubility of 
arachidonic acid in the buffer phase 
Control (buffer alone) 
401 0.5 mg/ml 
·401 1 mg/ml 
Ethy1 acetate 1[ Control 401 0.5 mg/ml phase 
401 1 mg/ml 
Total 
ŸŦĚArach. 
0.0004 
0.00134 
0.0016 
0.464 
0.460 
0.44 
each value represents the average of two determinations 
Acid 
The results presented in Table 3-X indicate that some complexing between 
peptide 401 and arachidonic acid is occurring. The results of Table 3-XI 
show also some complexing but not so pronounced. However the complexing 
observed is negligible in terms of substrate depletion as an explanation 
for the inhibition of PGE2 synthesis by peptide 401. The results in 
Table 3-VII and Fig. 3-8 show that only below a substrate concentration 
of,O.S mM would the synthesis of prostaglandin start to decrease. 
In the experimental conditions employed in the present work J the results 
in Tables 3-X and 3-XI show that the amount of uncomplexed arachidonic 
acid is still in a large excess over the complexed arachidonic aCid. 
Those results show that at an arachidonic acid concentration of 1 mM, 
the concentration of the free acid available as substrate for the 
enzymatic reaction would be approximately 0.54 mM. It should also be 
added that in the experiments employing the spectrophotometric method, 
where the substrate concentration was ÌĦÎİŸĚmM and ŴUŤŲŸĚpeptide 401 
was at a concentration of 0.6 mg/ml, the results in Table 3-II and 
Fig. 3-2 show that the inhibition by peptide 401 is comparable with the 
inhibition found using the radiochemical method (41% in the spectro-
photometric method and 42% in the radiochemical method). If 
complexing between arachidonic acid and peptide 401 was occurring the 
degree of inhibition at a substrate concentration of 0.273 mM should be 
greater than at 1 mM. Furthermore 'in Table 3-V it can be seen that 
melittin at a concentration of 0.5 mg/ml did not cause any inhibition 
of PGE2 synthesis, but ÙŸĚfact a slight activation. These results, 
together with the results in Table 3-VII and Fig. 3-8, suggest that 
peptide 401 is inhibiting the enzymatic complex rather than depleting 
the substrate. 
Finally, in Table 3-XII the results 'of experiments where 
peptide 401 was incubated with a prostaglandin synthetase complex 
obtained from bovine seminal vesicles, are presented. The method 
employed was exactly the same. In these experiments, two different' 
batches of peptide 401 were tested, as obtained from two different 
isolation procedures. Both batches of 401 were able to inhibit PGE2 
synthesis by approximately 97% at concentrations of 2 mg/ml. 
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Table 3-XII 
Effects of two different batches of 401 on PGE2 . 
synthesis by bovine prostaglandin synthetase 
Control 
Peptide 401 (2 mg/ml) BATCH I 
Peptide 401 (2 mg/ml) BATCH II 
? 
3-4 Discussion 
0.0474 
0.0011 
0.00085 
The experiments described in this chapter demonstrated that 
peptide 401 is able to inhibit PGE2 synthesis in vitro, when incubated 
with prostaglandin synthetases obtained from sheep and bovine seminal 
vesicles. A concentration of 401 of 1 mg/ml is able to inhibit PGE2 
synthesis by 87% and inhibition can be observed down to concentrations 
of 0.4 mg/ml. These results were obtained using two different assay 
systems for prostaglandins and employing two different batches of the 
enzymatic complex from sheep seminal vesicles. It was not possible to 
conclude whether this inhibitory effect of 401 reflects an action at 
the substrate site or at the cofactor site on the enzymatic complex. 
Likewise it was not possible to determine if any allosteric effects 
caused by 401 on the enzymatic complex were occurring, due to the 
74 
limited amount of the acetone-pentane powder containing the prostaglandin 
synthetase. It was found that some complexing was occurring between 
peptide 401 and arachidonic acid, but the degree of complexing was only 
residual and could not account for the inhibition observed. Melittin, 
which is another basic peptide from the bee venom, and which shares with 
peptide 401 the ability to degranulate mast cells, although it has no 
anti-inflammatory activity in the rat, did not inhibit the prostaglandin 
synthetase. The possibility that the ŠŪWÙŸÙŪȚŨŠÜÜŠWŬŲXĚactivity of 401 
could be explained by stimulation of synthesis of ÖŇŃÎŸGĚwhich in the 
rat carrageenan oedema has an anti-inflammatory activity, was ruled out 
since the synthesis of this prostaglandin was also inhibited by peptide 
8( 
401. This is in agreement with the results of Hanson et ale ĜŸĞĚwho 
showed that in the carrageenan oedema, injections of ÖŇŃÎŸĚ in the rats 
up to concentrations of 50 ŸŦIÛŦĚdid not cause an appreciable anti-
inflammatory effect. 
A large number of compounds have been reported which inhibit 
prostaglandin synthesis in vitro and in vivo (65). However, the variety 
of the chemical nature of these compounds, together with the lack of 
structural data about the multi-enzymatic system responsible for the 
synthesis of prostaglandins, makes it difficult to propose a mechanism 
by means of which these inhibitors are effective. It is Simpler to do 
so in the case of analogues of the essential fatty acids which are 
precursors of prostaglandins. Several of these analogues are inhibitors 
of prostaglandin synthesis either by acting directly on the enzymatic 
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complex or by preventing the hydroxylation reaction on the precursors (1). 
The direct inhibitory action of these acetylenic analogues of arachidonic 
acid on the enzymatic complex occurs presumably by destruction of the 
catalytic site on the enzyme (105). Another group of inhibitors are the 
·so called 'aspirin-like' drugs, which are thus named because they share 
the same pharmacological actions. These compounds show different 
degrees of inhibition depending on the experimental system employed, 
7G 
that is, whether acetone powders containing the PG synthetase, slices 
of organs or in vivo experiments in ŸUŤĚwhole animal are used. 
Differences in inhibitory potency can also vary from tissue to tissue 
for the same inhibitor (65). In this group compounds such as aspirin, 
indomethacin, paracetamol, phenylbutazone, "meclofenamic aCid, niflumic 
acid etc., are included. Most of these aspirin-like drugs are organic 
acids but whether the acid function is necessary for their activity is 
not certain since there are non-acidic aspirin-like inhibitors of 
prostaglandin synthesis. The inhibition of PG synthesis found with 
these compounds is assumed to be of a competitive nature, either for the 
substrate and/or cofactor sites of the enzymatic complex (65). Up to 
I 
date there has been no report of in vitro experiments where basic 
peptides or proteins were shown to inhibit the synthesis of prostaglandins 
directly. 
It should now be considered whether the observed in vitro 
inhibition of PGE2 synthesis by peptide 401 bears any relation to the 
anti-inflammatory activity of this peptide in the rat carrageenan oedema. 
Studies in the rat showed that peptide 401 injected subcutaneously or 
intravenously at concentrations of 0.25 mg/kg is able to suppress the 
local increased vascular permeability induced by carrageenan (81). Other 
reports (156) showed that peptide 401 at concentrations of 0.7 mg/kg is 
able "to reduce by 3a,% the oedema caused by carrageenan, although such 
ȘŬŪȘŤŪWŲŠWŸŬŪVĚof 401 were shown to have some systemic inflammatory t. 
effects ĜŸĞĦĚ It should be kept in mind, however, that the anti-
inflammatory activity of peptide 401 varies from one strain of rats to . 
ŸHĚ
another ĜŸĞĦĚ
Thus the in vivo doses of peptide 401 which are able to produce 
anti-inflammatory effects are smaller than the in vitro concentrations of 
" 
401, which were found'to inhibit PGE2 synthesis in the present work. 
This difference, however, TŬŸVĚnot necessarily exclude the possibility 
that the anti-inflammatory activity of peptide 401 could be associated 
with inhibition of prostaglandin synthesis in the rat. It is known 
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that different preparations of prostaglandin synthetase complexes show 
different sensitivities for a given inhibitor and that in the same 
animal the amount of the enzymatic system responsible for prostaglandin 
synthesis can vary from one tissue to another (65). There is no data 
available which would allow one to establish an equivalence between the 
amount of the enzyme used in the present work and that which would be 
found in the rat •. According to the classification of Christ and Van 
Dorp (35) the enzyme obtained from sheep seminal vesicles has 
comparatively a very high activity. Thus if a sufficient amount of 
prostaglandin synthetase could be isolated from the rat tissues it is 
Possible that peptide 401 would effectively inhibit prostaglandin 
synthesis at concentrations which produce anti-inflammatory responses 
in the rat carrageenan oedema. It is interesting to add that in the 
guinea pig, prostaglandins El and E2 lack the same inflammatory potency 
they have in the rat, and in the same animal, peptide 401 injected in 
concentrations up to 2 mg/kg fails to have any anti-inflammatory activity 
in the carrageenan oedema, although it still retains its ability to 
induce local increased vascular ŮŤŲÜŤŠŞŸÍÍWXHĚ probably due to 
,degranulation of mast cells (192, 81). 
Alternatively we can assume that peptide 401 is interacting 
specifically with a certain tissue. The consequence of such specific 
tissular interaction would be an increased local concentration of peptide 
ŸÕŨĦĚ If the tissue in question is involved in the inflammatory process 
and is responsible for the synthesis and release of prostaglandins at 
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the site of inflammation (since prostaglandins seem to be metabolized 
very quickly once they are released), one would have a situation where 
injections of relatively low doses of 401 could block thls source of 
prostaglandins and in this way significantly alter the course of the 
inflammatory process. So far the only suggestion concerning specific 
tissular interaction of peptide 401 comes from the work of Hanson et ale 
(81). who observed a hypotensive effect of peptide 401 when injected 
'. 
intravenously in the rat. Although this hypotensive effect of peptide t 
401 could be blocked by mepyramine and methy1sergide, it was found that 
even in the presence of these blockers of histamine and serotonin, the 
anti-inflammatory activity of 401 persisted. No vasoconstriction effects 
ȘŠẀVŸTĚby peptide 401 could be detected with doses of 401 up to 1 mg 
and likewise no selective vasoconstriction in the skin was obtained with 
peptide 401. It was VẀŦŸŤVWŤTĚthen that probably 401 was exerting its 
anti-inflammatory activity by interacting with the blood vessels and 
rendering them unresponsive to inflammatory agents, but again, as 
mentioned before, it was demonstrated in the same work that the anti-
inflammatory effects of peptide 401 do not seem to be dependent on any 
vascular action, since the'course of the inflammatory process proceeds 
even in the presence of antagonists of histamine and serotonin and 
suppression of inflammation by 401 also occurs in the presence of these 
antagonists. Furthermore, such an effect of peptide 401 on the vascular 
endothelium would require either that some kind of modification of the 
vaSCular tissue, induced perhaps by the inflammatory process, would 
favour this interaction or else that peptide 401 is evenly distributed 
throughout the vascular system of the rat. Both possibilities, however, 
would appear unlikely, as mentioned above. It appears that the only 
actions of peptide 401 on the vascular system are indirect ones; the 
local increase in vascular permeability induced by 401 and by melittin 
is probably simply reflecting the release of histamine due to 
degranulation of mast cells by these two compounds. 
On the other hand, considering that peptide 401 is able to 
degranulate mast cells in concentrations as low as 0.001 mg/ml (see 
. following chapter),it is reasonable to assume that there is a high 
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degree of interaction between peptide 401 and mast cells, which is 
probably also reflecting a binding pattern due to characteristic features 
on the membranes of these cells. It is also noteworthy that peptide 401 
at a concentration of 0.4 mg/ml shows some chemotactic activity for 
human neutrophils but none for monocytes. The chemotactic activity for 
neutrophils could be observed down to concentrations of 401 of 0.05 
mg/ml. However, much lower concentrations of peptide 401 (0.01 ŸŦIÜŨĞĚ
were able to produce chemotactic activity for human monocytes (191), again 
suggesting a high degree of interaction with a particular group of cells. 
These considerations indicate the possibility of· peptide 401 interacting 
specifically with leucocytes, which are not only ubiquitous, but which 
also migrate to the site of inflammation in the carrageenan oedema and 
there display an important role as secretory cells, releasing histamine, 
serotonin, hyalJronidases, proteases and prostaglandins. These features 
make leucocytes very probably target cells for peptide 401. Thus, the 
anti-inflammatory activity of peptide 401 could be explained at least 
partially as a consequence of inhibition of prostaglandin synthesis by 
the leucocytes. Attempts to investigate the effect of peptide 401 on 
prostaglandin synthesis by rat leucocytes obtained from peritoneal 
eXUdates, failed since the cells did not produce any measurable amount 
ŸȚĚprostaglandins, even in the presence of killed B. pertUSSiS, which 
induces intensive phagocytosis and hence prostaglandin formation and 
release. 
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Concerning the possible interaction between peptide 401 and 
the rat leucocytes with a resulting inhibition of prostaglandin synthesis, 
it was observed (26, 156) that the maximum anti-inflammatory activity 
of peptide 401 in the carrageenan oedema is observed between 3-5 h after 
the injection of carrageenan, which according to Di Rosa et ale (49) 
is the phase when cell migration to the site of inflammation is taking 
place, concomitantly with prostaglandin release. Higher doses of 401 
()0.25 mg/kg) injected into the rats would counterbalance the anti-
inflammatory effects by causing more release of histamine due to 
degranulation of mast cells and therefore masking the effects of 
inhibition of prostaglandin synthesis. This seems to be occurring 
locally after subcutaneous injections of peptide 401, when the local 
concentration of 401 is of such an order that only the inflammatory 
effects due to degranulation of mast cells are observed (81). 
If the idea of a specific interaction between peptide 401 and 
leucocytes, with subsequent inhibition of prostaglandin synthesis is 
correct, what structural features of the membranes of the leucocytes 
would be directing this interaction? The experiments described in the· 
next chapter were carried out in order to establish the binding 
characteristics of peptide 401 to model membrane systems and to determine 
if it is possible to extrapolate these conditions to the in vivo 
situation. 
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CHAPTER 4 
INTERACTIONS BETWEEN PEPTIDE 401, LEUCOCYTES AND LIPOSOMES 
4-1 Introduction 
4-1-1 Interaction between basic peptides and cell membranes 
In the last chapter it was suggested that peptide 401 could be 
exerting its anti-inflammatory activity by interacting specifically with 
leucocytes and inhibiting prostaglandin synthesis by these cells. 
It is known that several basic peptides and proteins are able 
to induce pinocytosis in a number of different cells (145, 122, 70) and 
it was suggested that such effects were the consequence of an imbalance 
in the repulsive forces between the mobile units of the biological 
membrane (70). These sub-units are generally negatively charged and 
their aggregation appears to be a preliminary stage in the pinocytic 
process. 
In some cases, the binding of basic peptides to the cell 
membranes is a consequence of ŤŨŤȘWŲŬVWŸWÙȘĚinteractions. It is believed 
that the presence of sialic acid on the membrane is a requirement for 
binding since these acid groups are largely responsible for the negative 
charge of the membrane (37). This seems to be the case for tuftsin, a 
tetrapeptide obtained by cleavage of the last 4 amino acid residues of 
leukokinin (36, 122), which binds specifically to blood polymorpho-
nucleocytes and stimulates their phagocytic activity. 
Although there is no data available about the spatial 
organisation of the peptide 401 molecule, which would allow comparison 
With other basic peptides, very possibly similar conditions may be 
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occurring which would then increase the probability of interaction 
between peptide 401 and the leucocytes. 
4-1-2 Labelling of peptide 401 
It would be of interest to study the fate of peptide 401 when 
injected into the ŲŠWŸĚ However, the problem concerning studies on the 
interactions between peptide 401 and the tissues resides in the difficulty 
of labelling peptide 401 in such a way as to preserve the biological 
,activity. Several attempts to synthesize peptide 401 have been made 
but success has not yet been achieved (199). Synthesis of peptide 401 
would allow the introduction of labelled amino acids into the molecule. 
The absence of tyrosine residues in the molecule of 401 eliminates 
, 131 introduction of I. Moreover the integrity of the histidine residues 
131 
which could also be labelled with I seems to be important for the 
anti-inflammatory activity, since experiments involving photo-oxidation 
of the peptide (156) demonstrated that anti-inflammatory activity is lost 
after ,exposure to light from a 100 W bulb for 1 h, in the presence of 
rose bengal (4,5,6,7-tetrachloro-2',4',5',7'-tetraiiodofluorescein) as 
a sensitizer. Introduction of compounds which react with the free amino 
groups of the lysine residues of 401, such as treatment with maleic acid 
anhydride and acetylation (partial or total) or reactions which destroy 
the disulphide bridges of 401 such as trlfluoroacetylation, aminoethylation, 
and carboxymethylation all produce derivatives which are inactive with 
" 
respect to anti-inflammatory activity (156, 27). 
4-1-2-1 Dansylation of peptide 401 
Treatment of peptide 401 with I-N,N-dimethylaminonaphtalene-5-
sulphonyl (chloride) (dansyl) yielded a derivative which retained some of 
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its ability to degranulate mast cells (see results). The dansyl-40l 
peptide was able to reduce the carrageenan oedema in the rat by 35% when 
f 
injected at a concentration of 3.5 mg/kg. Concentrations of 0.7'mg/kg 
produced 16% reduction of the oedema (156). The same amount of untreated 
401 should produce approximately 50% of reduction according to previous 
results on the anti-inflammatory activity of peptide 401. So, although 
the dansyl-40l peptide is about three times less potent in its anti-
inflammatory activity, the nearly unaffected ability to degranulate mast 
cells indicates that the binding of d-401 to the membranes of mast cells 
is not drastically altered. 
The product of dansylation of peptide 401 in a molar ratio 1:1 
was examined'by, TLC as described in Chapter 2 (N-terminal analysis), and 
found to be a mixture of different ninhydrin positive spots. This 
indicated that the dansyl groups had reacted unselectively with different 
amino groups of the molecule of peptide 401, and also that there could 
be molecules of peptide 401 which had reacted with more than one dansyl 
,group. However, although this would imply that some unreacted peptide 
401 must be present, the TLC plates showed no ninhydrin positive spot 
which was'not also associated with fluorescence. Therefore, the amount 
of unchanged peptide 401 must have been fairly small. Although some of 
the anti-inflammatory effects of d-40l could be due to the presence of 
trace amounts of unchanged peptide 401, it can be seen (Table 4-I) that 
the mast cell degranulating activity of peptide 401 was little affected 
by treatment with dansyl. These results would then suggest that most 
of the observed anti-inflammatory effects obtained with the d-401 
preparation were due to the dansylated products. 
The main advantage of using the dansyl labelled peptide 401 
, lies in the simplicity of studying its binding to the cell membranes, 
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at very low concentrations, by means of UV microscopy. In the first 
part of the following experiments the dansyl-40l peptide (d-401) was 
incubated in vitro with cell populations obtained from rat ŸŪTĚhuman 
blood, as well as cells obtained from rat peritoneum, in order to 
establish if any preferential binding betwe'en d-401 and ŸĚparticular 
group of cells was occurring. No attempts were made to study interactions 
between d-40l and other tissues, since the dilution (after injection of 
d-40l into ŸŠWVĞĚwould be too big to allow the visual detection of the 
peptide 'and also because the histological techniques involved in 
obtaining samples of the various tissues investigated would make this 
scanning impractical. 
4-1-3 Interaction between peptide 401 and different cell 
populations 
With the purpose of obtaining information about the interaction 
between the natural peptide 401 and the cell membranes the following 
approaches were considered: a) It was reasoned that by treating blood 
cells, as well as cells obtained from the rat peritoneum, with peptide 
401, some alterations on the membranes of the cells binding 401 would 
occur and possibly this would be reflected on the charge of these cells. 
By using the technique of cell electrophoresis the differences in. the 
charges of the cells affected by peptide 401 would become !pparent and 
.if any preferential binding of 401 occurred with a particular group of 
cells, the electrophoretic mobilities of these cells should be more 
altered than unaffected cells. b) By treating latex beads, which at 
pH 7 are slightly negatively charged, with peptide 401, some amount of 
peptide 401 would adsorb to the surface of the latex beads and after 
removing the unadsorbed peptide 401, it should be possible to see which 
----------
group of cells would bind more latex beads. As the results of both 
sets of experiments were inconclusive, they will not be quoted in this 
chapter. 
4-1-4 Liposomes 
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As an alternative, the effects of peptide 401 on model membrane 
systems, consisting of dispersions of lipids in aqueous solutions were 
studied. Aqueous dispersions of lipids also known as smectic mesophases, 
Bangosomes or liposomes consist of lipids, which can be isolated from 
the natural membranes and which, in contact with dilute aqueous solutions, 
spontaneously form closed multilammellar vesicles of concentric bilayers, 
containing aqueous spaces between them (16). If liposomes thus prepared 
are sonicated, closed vesicles presenting a single lipid bilayer can be 
obtained. The aqueous spaces of the liposomes can be made to contain 
the solutes of the aqueous solutions in which the lipids were dispersed, 
and the permeability rates of these trapped solutes can be easily 
measured by a number of different techniques. Permeability rates for 
several solutes as obtained from studies employing liposomes revealed 
that there is a striking similarity as compared to the same parameter 
in the biological membranes (16) and as the physical forces directing 
the structural association of the lipids in liposomes do not seem to 
differ radically from the ones in the cell membranes, as reflected by 
-a number of common features such as shape, thickness and some electrical 
properties, it is possible to investigate many basic processes inherent 
to the cell membranes employing liposomes, without being too far from 
reality. Such processes include adhesion phenomena, diffusion of 
solutes across membranes, interactions of proteins and peptides and 
antibiotics, structural organization of lipids and proteins on the 
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membranes and antigen-antibody-complement reactions (14). It should 
be kept in mind, however, that the degree of complexity of the cell 
membranes, due to the presence of proteins, is obviously far greater 
than in the liposomes. 
4-1-5 Interaction between peptide 401 and liposomes 
In the work described here, the effects of peptide 401 on 
the permeability rates for glucose, as a non polar solute, and for 
22 + 
'Na of 1iposomes prepared with the phospholipids phosphatidyl choline 
(lecithin), phosphatidyl serine and phosphatidic acid together with 
cholesterol, were studied. The aim of such experiments was to determine 
22 + if any effects of peptide 401 on permeability rates to glucose and Na, 
could be correlated with the lipid composition of the liposomes and 
consequently charge and hydrophobicity of these membranes, hoping that 
parallels could be drawn with the in vivo situation. Thus the model 
membrane system employed in this work should give an indication whether 
the binding of peptide 401 to the cell membranes is simply.due to non-
specific electrostatic forces as a consequence of the basicity of the 
mOlecule of 401, ŬŸĚif there are any other factors involved directing 
the binding of 401, which if displayed by a tissue in vivo, could favour 
specific interaction • 
• 4-2 Materials and methods 
Experiments with da'nsyl-40l 
The dansyl-401 peptide was prepared by Dr. R.A. Shipolini from 
this department following ŸUŤĚmethod described in Chapter 2. Peptide 
401 was treated with dansyl in molar ratios of 1:1 and 1:2 (401:dansyl). 
Rat mast cells were obtained by injection of 10 ml of phosphate buffered 
. ' 
isotonic saline containing 50 ŸŦIÜŨĚof heparin into the peritoneum of 
rats (killed e1ther with a blow on the head or with etner). After 
massaging for a few m1nutes, the peritoneum was opened and the exudate 
was collected by means of a Pasteur pipette. The cell population thus 
obtained presented a proportion of 9 mast cells for every other 80 
cells, which included lymphocytes and macro phages. 
Rat leucocytes were obtained by injecting 100 i.u. of 
heparin into the peritoneum of the rats and after 3 min the rats were 
decapitated and the blood was collected in a beaker containing ZOO i.u. 
of heparin. To the total blood, plasmagel (Laboratoire Roger Bellon) 
was added in a ratio 3/4, v/v (blood/plasmagel). The blood was then 
left to sediment at room temperature for ZO min and the supernatant 
(containing the leucocytes and red cells too) was .then collected and 
washed in isotonic saline, using a bench centrifuge. 
Human blood was collected with heparin by venous puncture. 
4-2-1-1 Assay for degranulation of mast cells 
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To test the ability of the modified 401 to degranulate mast 
cells, wistar rats, weighing about ZOO g were injected i.p. with peptide 
d-40l dissolved in the phosphate buffered saline, pH 7.4 (8.1 g NaCl, 
2.272 g Na ZHP04, 0.544 g KHZP0 4 in 1000 ml HZO). After 15 min the rats 
were·killed and pieces of the mesenteric fat were spread on microscope 
, slides, fixed and stained with 0.2% toluidine blue in 10% formaldehyde, 
5% acetic acid and 50% ethanol. Intact and degranulated mast cells were 
then counted. 
The anti-inflammatory activity of the d-40l peptide was assayed 
ŸVÙŪŦĚthe rat carrageenan oedema. 
4-2-1-2 Interaction between d-40l and cells 
To detect if any interaction was occurring with the d-40l 
peptide, the cells obtained from the different sources were incubated 
with d-401, dissolved in the PBS buffer pH 7.4 for 10 min at 37 0 C in 
8S 
centrifuge tubes. The cells were then centrifuged in a bench centrifuge 
at low speed, resuspended in a small amount of buffer and observed in a 
Wild microscope equipped with an HEO 200 mercury lamp, using a GG 13 
filter for ultraviolet fluorescence. 
When measuring the interaction of human red cells with d-401, 
several dilutions of the blood were incubated with d-40l dissolved in 
isotonic saline for 15 min at room temperature. The blood suspension 
was then centrifuged for 5 min in a bench centrifuge and the supernatants 
were collected and kept in ice. The precipitate containing the red cells 
was washed once with 5 ml of saline and also kept in ice until used. 
The fluoresence intensity of the supernatant solutions and 
the precipitate was then measured in a Perkin-Elmer fluorescence 
spectrophotometer, model MPF-3, using an excitation wavelength of 332 ÜŸĚ
and emission of 520 ÜŸHĚ which corresponds to the fluorescence peak 
obtained for d-401 alone. 
4-2-2 Experiments using liposomes 
All the materials used in the present work were used without 
,further purification and were of the highest purity available. 
D(+) glucose grade III, Trizma base, glucose-6-phosphate dehydrogenase 
(type XV) from baker's yeast (300 units/mg protein), ATP, NADP and 
cholesterol were purchased from Sigma Chemical Co. Hexokinase, phosphatidyl 
choline, phosphatidic acid and phosphatidyl serine were purchased from 
-
Koch-Light Laboratories. Phosphatidyl choline (lecithin) in a 
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concentration of 0.1 glml, and phosphatidic acid (10 mg/ml) were stored 
o 
under nitrogen in sealed ampoules at -20 C, in aliquots of 0.05 ml. 
For each preparation of liposomes a fresh ampoule was used. 22Na+ in 
the form of sodium chloride in aqueous solution ( 100 mcilmg Na) was 
purchased from The Radiochemical Centre, Amersham, and Triton X-100 
(iso-octyl-phenoxypolyethoxy ethanol containing 10 mols of ethylene 
oxide) was obtained from BDH Chemicals Ltd. Dialysis membranes (Visking) 
were obtained from Medicell International. Before every experiment, the 
dialysis membranes were soaked overnight in the solution used for 
dialysis. 
All aqueous solutions were made with either triple distilled 
water or with deionized water which was subsequently distilled in an 
all glass apparatus. 
4-2-2-1 Preparation of glucose liposomes 
The method for preparing the glucose liposomes was based on 
that described by Kinsky et ale (45, 100). Aliquots of the lipids in 
either chloroform or ethanol solutions were collected to make the 
desired molar concentration of the lipids in the aqueous solutions. 
The lipid solutions were pipetted into 5 ml round bottom flasks and the 
solvents were removed under a stream of N2'while the flask revolved, 
connected to the roto evaporator. This produced a film of the lipids 
• adhering to the walls of the flask. Traces of the solvents were then 
, removed under vacuum for 10 min. To the dry film of lipids, 0.5 ml of 
a 0.3 M glucose solution was pipetted into the flask, which was then 
transferred to a water bath at 40oC. The flask was turned manually 
until all the lipids were dispersed and then it was stirred for 30 secs 
on a Vortex mixer. The liposomes prepared in this way will be referred 
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to as mechanically dispersed. After stirring, the liposomes were left 
I 
standing at room temperature, with occasional stirring, foi 1.5 hand 
then dialyzed.for 1 h against 1500 ml of an isotonic solution containing 
0.075 M KCl and 0.075 M NaCl. The system used for dialysis is described 
in Fig. 4-1. Dialysis was carried out at rdom temperature with the 
dialysis bag being turned very slowly with an electric motor (2i RPM) 
in such a way as to allow an air bubble inside the bag to stir the 
liposomes gently. During dialysis the isotonic solution was constantly 
-bubbled with nitrogen. It,was found that when synthetic phospholipids 
were used, apart from having to introduce glass beads into the round 
bottom flasks and stir it on the Vortex mixer in order to disperse the 
lipid film, very little glucose was trapped inside the liposomes, probably 
due to the presence of saturated fatty acids on the phospholipid 
molecule (45). 
After dialysis, the leakage of glucose from the liposomes was 
either measured directly inside a spectrophotometric cell or by means of 
equilibrium dialysis. The direct method consisted of adding to a 
spectrophotometric cell (quartz, 10 mm light path) the following solutions: 
0.28 ml of 0.1 M Tris buffer pH 8, 0.5 ml of a solution containing 0.15 M 
KCl and 0.15 M NaCl in Tris buffer pHS, 0.1 ml of 0.02 M magnesium 
acetate, 0.05 ml of 0.02 M ATP, 0.1 ml of 0.01 M NADP, 0.005 ml of 
heXOkinase (6.7 mg/ml) and 0.005 ml of glucose-6-phosphate dehydrogenase 
(3.4 mg/ml). In the reference cell only NADP was omitted. The reaction 
was started by addition of 0.005 ml of the liposomes to the cells and 
the glucose leakage was measured by following the increase in absorbancy 
at 340 ÜŸĚusing a Unicam SP 500 spectrophotometer. The increase in 
absorbancy is due to the formation of NADPH resulting from the following 
sequence of reactions: 
o 
FIG 4·1 -Dialysis system used for the glucose 
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GLUCOSE + ATP - HEXOKINASE > GLUCOSE-6-PHOSPHATE 
GLUCOSE-6-PHOSPHATE + NADP GLUCOSE-6-P.- -DEHYDROGENASE ) 
__ ŸĞĚ 6-PHOSPHOGLUCONATE + + NADPH + H 
When peptide 401 was tested for its effect on glucose permeability, it 
was either pre-incubated with the liposomes for 15 min at room temperature 
and then the liposomes were added directly to the spectrophotometric 
ce_lls as described, or else a solution of 401 was added directly to the 
spectrophotometric cells containing the liposomes after the initial 
glucose leakage had been measured for a given interval of time. To 
estimate the total glucose content of the liposomes, 0.1 ml of a ŨŸĚ
-solution (v/v) of Triton-X-IOO was added to the cells; this was 
sufficient to break the liposomes and thus release all the glucose 
trapped. 
The equilibrium dialysis method consisted of pipetting 0.1 ml 
aliquots of the liposomes into dialysis bags which were then placed 
inside test tubes filled with 3 ml of the isotonic solution (0.075 M 
NaCl + 0.075 M KC1) containing the substance to be tested. The tubes 
(see Fig. 4-2) were then incubated at 40°C for 1 h and then aliquots of 
the solution bathing the dialysis bags were assayed "for glucose as 
described before. 
4-2-2-2 22 + Preparation of Na liposomes 
The preparation of the 22Na+ liposomes was conducted essentially 
as described for the glucose liposomes, except for the solutions used in 
the dialysis step and the ŸŠŨXVÙVĚsystem itself. 
22 + After obtaining the dry film of lipids 5-10 ŸȘÙĚof Na were 
added to the round bottom flask together with a known volume of the. 
FIG 4-2 
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aqueous solutions (the volume depended on the amount of liposomes needed 
for a particular experiment or on the desired molar ratio of the lipids) 
o 
and dispersed at 37 C as described before. In some cases the liposomes 
were sonicated using a bath type sonicator (American Beauty S 30) in 
plastic test tubes, until the dispersion became clear and slightly 
bluish. The aqueous VŬŨẀWÙŬŸVĚused for the dispersion and dialysis of 
the liposomes were either a TES buffer pH 7.4, made of 100 mM NaCl, 
2mM TES eN-Tris hydroxymethyl-2 amino ethane sulphonic acid), and 
2 mM histidine, or a phosphate buffered saline pH 7.4. The liposomes 
were dialysed against the solutions in which they were dispersed using 
the system described in Fig. 4-3. 
The plastic bottle contained 150 ml of buffer and was 
rotated for 15 min - 30 min each time. The solution was then replaced 
by ŸĚfresh one and the ŮŸŬȘŤVVĚwas repeated. For each liposome 
preparation 4 changes of the solution were made. The liposomes prepared 
in this way were incubated inside ,dialysis bags as described for the 
glucose liposomes. Incubation was carried out for 3 h at 37oC. Aliquots 
of the solutions bathing the dialysis bags were then collected (0.05 ml) 
for counting in a Beckman liquid SCintillation spectrometer, using the 
same scintillation fluid described in Chapter 3. 22 + The Na was counted 
32 
using the P channel of the spectrometer which gave a counting 
efficiency of 22 + The total amount of Na trapped in the liposomes 
was estimated by counting an aliquot of the liposomes after dialysis, 
added directly to the scintillation vials. 
FI G 4-3 - Dialysis system used for the 22Na + liposomes 
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4-3 Results 
4-3-1 Mast cell degranulation 
The results of the tests on the ability of d-401 to degranulate 
mast cells are presented in Table 4-I. 
Table 4-I 
Effect of untreated 401 and d-401 on mast cell degranulation 
Control (no injection) 
401 (untreated) 0.1 Ilg/ml 
401 (untreated)' 1 Ilg/ml 
401 (untreated) 10 Ilg/ml 
401 (treated with 1:1 mol ·0£ dansyl) 
1 Ilg/ml 
401 (treated with 1:2 mols of dansyl) 
1 Ilg/ml 
% degranulated 
mast cells 
o 
o 
1 
2 
o 
1 
66 
89 
82 
98 
97 
99 
68 
64 
25 
30 
41 
29 
Mean 8c S.D. 
79 .! 11 % 
98 .! 1 % 
52 .!. 23 % 
33 .! 6 % 
As the peptide treated with 2 mo1s of dansyl presented less activity in 
degranulating mast cells than the 1:1 treated peptide 401, only the. 
latter was used in the interaction stUdies with 1eucocytes and red cells. 
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4-3-2 ŅŪWŤŲŠȘWÙŬŪŞŤWŸŤŤŲÙĚTŸÏŞŨĚŸWŸŸĚĬŸÍÍŸĚŞŞWŸÙŪŤTĚfrom the 
rat peritoneum 
Plate 4-1 shows mast cells obtained from rat peritoneum which 
have been ÙŪȘẀŞŠWŸTĚwith d-401 in a concentration of 0.1 mg/ml, and 
photographed under UV lighto It can be seen that although the mast cells 
Plate 4-1 - Leucocytes from rat peritoneum treated with d-40l 
Were fluorescing much more intensely, the ly.mphocytes present in the 
same cell population and appearing on the left, were also binding some 
d-401 o It was observed in the same experiment that addition of 1 ml of 
a fixative consisting of 50% ethanol , 10% formaline, and 5% acetic acid 
in distilled water, after incubation with d-401, did not interfere with 
the binding of d-401 to the cells, as judged by the unaltered 
fluorescence of the cellso 
4-3-3 Interactions between d-401 and rat blood cells 
Plates 4-2 and 4-3 show a population of leucocytes and red 
cells obtained from rat blood, which were incubated with d-401 at a 
97 
----------
, 
• 
r 
• 
Plate 4-2 - Rat leucocytes and red cells treated with d-40l ; the 
photograph was taken with the light from a tungsten 
l a mp 
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Plate 4- 3 - Same as above but with photograph t aken with U. V. light 
o 
concentration of 0.5 mg/ml at 37 C. In this preparation there were 
24 x ÍÌŸĚleucocytes present (as counted by means of the stain crystal 
blue 1%, which lyses the red cells), of which polymorphonucleocytes 
comprised about 70%, the rest being monocytes and cells which could not 
be identified. The photograph in Plate 4-2 was taken ŴÙŸUĚvisible 
light and Plate 4-3 is the same field but with the photograph taken 
under UV light. It can be seen that only the leucocytes present 
fluoresce, although it is not possible to distinguish which among the 
leucocytes are binding d-401. In all the fields examined the red cells 
were either not fluorescing at all or presenting only a very faint 
fluorescence. 
4-3-4 Interaction between d-401 and human red cells 
The results of experiments where the binding between d-401 and 
human red cells 'was investigated are presented in Table 4-11. 
Table 4-II 
Binding of d-401 to several.dilutions of human red blood cells 
Supernatant Dilution 
0.1 / 10 
0.5 / 10 
1/10 
2 / 10 
Fluorescence 
Intensity 
55 
65 
.64 
56 
In the above experim.ents, 0.1, 0.5, 1 and 2 m1 of total blood was 
diluted to 10 m1 with an isotonic NaC1 solution, containing 0.5 mg of 
99 
100 
d-40l and incubated for 15 min at room temperature. The cells were then 
centrifuged and the fluorescence intensity of the supernatant was 
measured as described before. The results in Table 4-II indicate that 
the red cells did not bind d-401 since all the fluorescence due to d-401 
seemed to be present in the supernatant. This was calculated based on 
a standard curve made with several dilutions of d-401 in plasma and with 
the same dilutions of the isotonic saline as for the experiments with the 
red cells. The curve thus obtained is presented in Table 4-III. 
Table 4-II1 
, 
Standard concentration-fluorescence curve for d-401 diluted in plasma 
d-40l (Ilg/ml) 
2 
10 
20 
40 
4.5 
12.5 
21.5 
39.5 
The precipitate containing the red cells showed only a residual 
fluorescence, which was probably due to scattering effects. In order to 
decrease the scattering, the cells were lysed with Triton X-100 and this 
solution presented no fluorescence at all. Although the released 
haemoglobin could have produced a quenching of the emitted light, or 
even of the exciting light, the results in Table 4-II indicate that the 
fluorescence found in the supernatant accounted for the whole amount of 
d-401 incubated with the cells, based on the curve presented in Table 
4-III. 
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4-3-5 Liposomes 
Plate 4-4 shows a preparation of liposomes made of lecithin 
and phosphatidic acid (8.6 mM and 0.45 mM respectively). Liposomes 
made of other lipids, or prepared with different molar ratios of the 
phospholipids do not show any apparent morphological differences at the 
low magnification at which the photograph in Plate 4-4 was taken, although 
liposomes containing cholesterol appeared to be smaller than the others. 
Plate 4-5 shows the aggregation caused by peptide 401 on the same 
preparation of liposomes. Aggregation caused by peptide 401 could be 
observed in all preparations of liposomes whether they contained 
phosphatidic aCid, phosphatidyl serine or not, indicating that the 
presence of negative charges was not necessary for this effect. 
Aggregation caused by peptide 401 could be observed down to 
concentrations of 0.2 mg/ml. Possibly this effect of peptide 401, which 
could also be induced with polylysine is reflecting a disruption of the 
colloidal equilibrium, either due to blocking of charges (in the case 
ofliposomes bearing negative charges) or to some kind of bridging between 
liposomes. However, it is not obvious why this should happen with 
liposomes made of neutral lipids. 
4-3-5-1 Glucose liposomes 
The results of adding several known concentrations of glucose 
, to the medium containing all the components of the coupled enzymatic 
assay system for glucose, on the absorbance at 340 nm are presented in 
Table 4-IV. These results were used as the standard curve from where 
. the glucose leakage from liposomes was calculated. Glucose leakage 
\ 
from the liposomes is expressed as the percentage of the total amount of 
glucose ( in ŸĚmoles) trapped in the liposomes, which permeated across 
Pl a te 4- 4-Liposomes made of l eoithin and phosphat i dio aoid 
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Pla te 4-5-Same preparat ion of 1ipos omes as above , but treated 
with peptide 401 
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the liposomes in 5 minutes. 
Table 4-IV 
Calibration of .the .glucose enzymatic assay 
''\ 
Glucose concentration Absorbance 
·(mM) ---. -340 nm 
(n = 2) 0.143 .414 
(n = 3) 0.286 .810 
(n = 3) 0.429 1.239 
.. 
-
...... -
Table 4-V presents the results of experiments in which peptide 
401 was pre-incubated ŴÙŸUĚthe liposomes (lecithin 8.6 mM and phosphatidic 
acid 0.45 mM) for 15 min at rOOm temperature before the glucose assay. 
Effect of-peptide 401 on glucose permeability 
Total amount trapped 
in the liposomes 
ĜŸÜŬŨVĞĚ
Percentage of glucose 
leakage in 5 min 
Control (n=6) 76.1 ŸÓĚ
Mean and .S.D •... 401(0.2mg/ml) 
Mean and ŐŸMĦĚ
177 ! 20 179 ! 29 
1.63 ! 0.5 1.97 ! 0.78 
each value repr.esents.the average of three .determinations 
It can be seen that there are no significant differences between glucose 
leakage of the two groups. 
Fig. 4-4 shows the results of adding peptide 401 directly to 
the spectrophotometric cell. These liposomes were made of lecithin 
8.6 roM and ŮUŬVŮUŸWÙTÙȘĚacid 0.45 mM. Peptide 401 final concentration 
was 0.02 mg/l.l mI. A very slight decrease in the permeability rate 
for glucose can be seen after addition of peptlde 401. The decrease in 
O.D. immediately after addition of the test substances is an artifact 
caused by dilution. The experiment presented in Fig. 4-4 was repeated 
three more times with Similar results and no apparent effect on the 
. permeability rate for glucose due to 401 could be observed. 
Table 4-VI shows the results of experiments where liposomes 
made of lecithin 8.6 mM and phosphatidic acid 0.45 mM, were incubated 
with peptide 401 in a concentration of 0.16 mg/ml, using the equilibrium 
dialysis system. 
Table 4-VI 
Effect of peptide 401 on glucose permeability 
using the equilibrium dialysis system 
Control 
401 (0.16 mg/ml = 60.8 ŸÓĞĚ
ŸĚMols glucose/h 
lOS.!. 11 
103 .!. 10 
each value represents the.average-of.5 determinations 
ŸĦĚ
The results are expressed as ŸĚmols of glucose present in the isotonic 
solution (0.075 M NaCl + 0.075 M KCl) bathing the dialysis bags, after 
o' 1 hour of incubation at 40 C. The results of the experiments measuring 
glucose leakage across mechanically dispersed liposomes, show that 
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peptide 401 at concentration ranges of 0.16 mg/ml - 0.2 mg/ml does not 
affect permeability rates for glucose of liposomes made of 8.6 mM 
lecithin and 0.45 mM phoaphatidic acid. 
4-3-5-2, 22 + Na liposomes 
22 + The counting efficiency for . Na in the scintillation 'fluid 
containing Triton X-100 was 48.9%. The quenching data presented in 
Table 4-VII was obtained by plotting the counting efficiencies against 
the external''standard ratio of the Beckman spectrometer. Quenching was 
106 
obtained by means of stepwise addition of chloroform to a sample of known 
activity. 
Table 4-VII 
Quenching curve for 22 + ,.Na _ 
Counting ESR (external 
Efficiency standard ratio) 
48.86 0.966 
49.18 0.914 
49.29 0.874 
49.52 0.834 
49.67 0.755 
49.51 0.700 
49.31 0.643 
49.13 0.528 
48.98 0.432 
48.37 0.187 
48.12 0.110 
47.33 0.026 
44.66 - ,,. --- 0 
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22 + The results of the experiments measuring Na permeability are expressed 
22 + 
as the percentage of the total amount of Na (in CPM) trapped in the 
liposomes after dialysis, which permeated across the 1iposomes after 
3 hours incubation at 37oC. The results in Table 4-VITI were obtained 
after incubating 1iposomes made of 5.37 mM'lecithin and.0.28 mM 
phosphatidic acid with several concentrations of peptide 401. The 
liposomes were dispersed in the TES buffer pH 7.4 which contained 
22 + 5 ŸȘÙĚof Na. 
Table 4-VIII 
22 + Effect of peptide 401 on Na leakage from 1iposomes made of 
lecithin (5.37 mM) and-phosphatidic-acid-(0.28.mM) 
Control 
401 (0.1 mg/ml = 38 ŸÓĞĚ
401 (0.02 mg/ml = 7.6 ŸÓĞĚ
401 (0.004 mg/m1 ŸĚ 1.52 ŸÓĞĚ
401 (0.0008 mg/m1 = 0.3 ŸÓĞĚ
401 (0.00016 mg/ml = 0.06 ŸÓLĚ
Triton X-100 (0.4%> 
22 + Total amount of Na trapped in 
the liposomes 
22 + % Total Na 
5.13 .!. 1.84 
8.3 + 2.3 
-
5.8 + 0.69 
-
5.9 + 
-
0.19 
7.36 .!. 0.88 
5.8 .! 1.2 
75 % 
12551 DPM 
each value is the .average of .-three --determinations 
In these experiments it can be seen that concentrations of 401 
of 0.1 mg/m1 and 0.0008 mg/m1 were able to produce an increase in the 
108 
22 + Na permeability. Although the variation observed in the results of 
this particular set of experiments made the interpretation somewhat 
diIficu1t, such effects could be reproduced, as shown in Fig. 4-5. 
Moreover, it has been shown that similar effects occur when very low 
concentrations of po1y1ysine were incubated with 1iposomes (99). It 
remains unclear why such low doses of a basic peptide are more effective 
in increasing the 22Na+ permeability, than high ones. In the case of 
po1y1ysine, and possibly in the case of peptide 401 too, very low 
concentrations may be interacting with the phospholipids in such a way 
as to rearrange them causing the formation of sodium'channe1s'. Higher 
concentrations, on the other hand, would have lytic effects on the 
membrane. 
It is believed that po1y1ysine is able to disrupt the 1iposomes, 
at relatively high concentrations by inducing a concentration of charges 
On the surface of the 1iposomes (77). However,the results with 1iposomes 
in which glucose was trapped, did not indicate that peptide 401 was 
causing any lytic effects. 
Table 4-IX and Fig. 4-5 show the results of experiments where 
1iposomes made of lecithin 5.37 mM and phosphatidic acid 0.28 mM 
, 22 + dispersed in the TES buffer pH 7.4 containing 10 ŸȘÙĚof Na, were 
incubated with peptide 401 in the same range of concentrations as in 
the experiments presented in Table 4-VIII. In these experiments, however, 
part of the 1iposomes were submitted to sonication for 30 min at 50-55 
k Hz yielding a dispersion which was clear and bluish. This indicated 
the presence of much smaller 1iposomes containing single bi1ayers of 
lipids instead of the mu1ti1ame11ar structure of the mechanically 
• 
dispersed 1iposomes. 
.. 
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Table 4-IX 
Effect of peptide 401 on sonicated and ·non-sonicated liposomes 
% of 22Na + 
Non-sonicated Sonicated 
Control 6.8 5.9 
401 (0.1 mg/ml) 10.8 13 
401 (0.02 mg/ml) 6.3 11 
401 (0.004 mg/ml) 6 11 
401 (0.0008 mg/ml) 6.4 8.2 
401 (0.00016 mg/ml) 6.21 11.7 
TX-IOO (0.4% .v/v) 78 % 91 
22 + Total amount of Na 15555 DPM 3045 DPM trapped in the liposomes 
each value is the· average of two determinations. 
Concentrations of peptide 401 of 0.1 mg/ml are able to increase the 
22 +. . permeability to Na in the non-sonicated and sonicated liposomes, 
although the sonicated liposomes appear to be more sensitive to 401 
since the whole range of concentrations of 401 is able to induce an 
22 + increased Na permeability in those liposomes. This fact indicates 
that the effective concentrations of 401 in the mechanically dispersed 
22 + liposomes, with respect to increased Na permeability, may be smaller 
than the ones reported, since the observed effect on 401 on the 
mechanically dispersed liposomes may be apparent only after 401. has 
22 + 
allowed leakage of Na ȚŸŬÜĚseveral adjacent compartments of the 
multilamellar structure. Thus, for the sake of interaction, the 
sonicated liposomes reveal that 401 is able to produce an increased 
, FIG 4-5 -'Effect of peptide 401 on permeability.rates 
of sonicated and non-sonicated liposornes 
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22 + Na permeability at very low concentrations, and there is no reason 
to assume that the lipid distribution in the sonicated liposomes is 
different from the mechanically dispersed ones. 
Table 4-X shows the results of incubating liposomes made of 
lecithin 5.37 mM and phosphatidic acid 0.28 mM and also made of lecithin 
5.37 mM and cholesterol 2.15 mM, both dispersed mechanically in theTES 
buffer pH 7.4, with several concentrations of peptide 401. 
Table 4-X 
22 + Effect of peptide 401 on Na leakage from 
liposomes containing or not cholesterol 
ŸÎÎÔŠĢĚ(Mean and S.D.) 
Control 
401 (0.2 mg/ml = 76 ŸÓĞĚ
401 (0.1 mg/ml = 3e ŸÓĞĚ
401 (0.05 mg/m1 = 18 ŸÓĞĚ
401 (0.01 mg/m1 = 3.6 ŸÓĞĚ
Triton X-100 (0.4%). 
22 + Total amount of Na. 
trapped 
Cho1estero1(2.15roM) 
Lecithin (5.37mM) 
16.6 .:!. 2.17 
10.6 .! 0.4 
9.64 .! 2.3 
11.8 .! 2.9 
46 ... 
2985 DPM 
Lecithin (5.37 mM) 
Phosphatidic 
Acid (0.28 roM) 
6.19 .! 2.22 
14.36 .! 6 
8.5.! .1.6 
8.8.:!. 0.42 
7.2.! 0.7 
63 
.. -28192 DPM 
each value is. the .average.o'£ .. three .determinations-
22 + The effect of peptide 401 in increasing Na . permeability can only be 
Observed in the liposomes containing phosphatidic aCid, indicating that 
112 
the presence of negative charges favours interaction between peptide 401 
and the membranes. The liposomes containing cholesterol trapped much 
22 + less Na than the lecithin-phosphatidic acid liposomes. It is possible 
that because the liposomes containing cholesterol are neutral at the pH 
of the experiments, Na+ ions diffuse more freely. Althqugh cholesterol 
liposomes appeared to be smaller than the phosphatidic acid-lecithin 
liposomes upon microscopic observation, and therefore contained less 
22 + 
. Na, the values presented in Table 4-X show that the control liposomes 
22 + 
containing cholesterol, in spite of having trapped less Na, showed a 
. 22 + higher ŮŤŲÜŤŠŞÙŨŸWXĚrate for Na than the control liposomes made of 
. lecithin and phosphatidic acid. 
In order to test if the charge alone of the liposomes was 
22 + important for the binding and the increased Na permeability effect of 
401, experiments were ma4e in which phosphatidic acid was replaced by 
phosphatidyl serine, another acidic phospholipid. 
Table 4-XI and Fig. 4-6 show the results ŸȚĚincubating 
liposomes made of lecithin 5.9 mM and phosphatidyl serine CPS) 9.12 roM 
and also liposomes made of lecithin 5.9 mM, PS 9.12 mM and cholesterol 
2.35 mM with peptide 401 in concentrations of 0.2 mg/ml and 0.1 mg/ml.' 
The liposomes were dispersed mechanically in TES buffer pH 7.4. 
Table· ÏŸÞŅĚ
22 + . Effect of peptide 401 on Na leakage from liposomes made of 
lecithin 5.9 mM, phosphatidyl serine 9.12 roM and containing or 
.not cholesterol 2.35.mM ... 
Lecithin 5.9 roM 
PS - 9.12 mM 
Lecithin 5.9 mM r 
PS - 9.12 mM 
Chol - 2.35 mM 
Control 
401 (0.2 mg/ml) 
401 (0.1 mg/ml) 
TX-IOO (2.5%) 
Total amount of 22Na+ 
trapped 
Control 
401 (0.2 mg/ml) 
401 (0.1 mg/ml) 
TX-IOO (2.5%) 
Total amount of 22Na+ 
trapped 
% 22Na+ leakage 
in 3 h 
8.98 .! 0.6 
.12 •. 49 .! 1 
9.48 .! 1 
34.3 + 5.9 
172 215 DPM 
8.11 .! 1.69 
13.51 .! 0.6 
10.7 .! 0.25 
31;5 + 2.75 
160 486 DPM 
each value is the average-of four determinations 
22 + The increased Na permeability effect of 401 can be observed in both 
liposome preparations with approximately the same degree. The same 
experiment was then repeated, but with a different ratio between 
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phosphatidyl serine and cholesterol. It was reasoned that in the previous 
experiment, the negative charges due to phosphatidyl serine were in a 
large excess and would thus be masking any effect of cholesterol on the 
binding of 401 to the lipo·somes. The results of this experiment are 
presented in Table 4-XII and Fig. 4-7. The liposomes were prepared with 
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. FIG 4·6 - Effect of peptide 401 on 22Na + permeability 
rates of liposomes made of several lipids. 
o 
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lecithin 5.9 mM and PS 1.82 mM and also with lecithin 5.9 mM, PS 1.82 mM 
and cholesterol 2.58 mM. 
Table 4-XII 
22 + Effect of 401 on Na leakage from liposomes made of lecithin 5.9 mM, 
phosphatidyl serine .1.82 .mM containing or not cholesterol 2.58 mM 
5.9 LEC 
1.82 PS 
5.9 LEC 
1.82 PS 
2.58 CHOL 
Control 
401 (0.2 mg/ml = 76 ŸÓĞĚ
401 (0.1 mg/ml = 38 ŸÓĞĚ
Triton X-IOO (2.5%-v/v) 
22 + Total amount of Na. trapped 
Control, 
401 (0.2 mg/ml) 
401 (0.1 mg/ml) 
Triton X-IOO (2.5% v/v) 
22 + % Na leakage in 3h 
" 9.16 .:!:. 0.37 
9.28 .:!:. 0.34 
9.75 .:!:. 0.43 
67 .:!:. 15.6 
_0.0_25 536 DPM 
% 22Na+ leakage in 3h 
4.55 .:!:. 0.27 
4.35 .:!:. 0.6 
4.85 .:!:. 0.41 
52.3 .:!:. 11.1 
36 250 DPM 
each value is the average of four determinations 
22 + It can be seen that no effect of 401 in increasing the Na permeability 
occurred in either group of liposomes, although both preparations were 
visibly aggregated indicating that some binding of 401 to the liposomes 
took place • 22 + A decrease in Na permeability in the liposomes containing 
. cholesterol can also be seen, although these liposomes trapped more 
22Na+ than the lecithin-PS liposomes. 
Table 4-XIII and Fig. 4-8 show the' results of experiments where 
FIG 4·7 - Effect of peptide 401 on 22Na+ permeability rates 
of 1iposomes with different lipid composition 
(data from Table 4-XII) 
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liposomes made of 5.4 mM PS alone, PS 5.4 mM + lecithin 5.25 mM and 
PS 5.4 mM + cholesterol 5.96 mM dispersed mechanically in a phosphate 
buffered saline pH 7.4 were incubated with peptide 401 in concentrations 
of 0.2 mg/ml and 0.1 mg/ml. 
Table 4-XIII 
Effect 
22 + . 
of peptide 401 on Na leakage from liposomes made of phosphatidyl 
serine (5.4 mM) alone, phosphatidyl serine (5.4 mM) + cholesterol (5.96 mM) 
and phosphatidyl serine (5.4 mM) + lecithin-(5.92 mM) 
5.4 mM PS 
5.4 mM PS 
5.96 mM CHOL 
5.4 mM PS 
5.92 mM LEC 
Control 
401 (0.2 mg/ml) 
401 (0.1 mg/ml) 
TX-IOO (2.5%) 
. . 22 + 
Total amount of Na trapped 
Control 
401 (q.2 mg/ml) 
401 (0.1 mg/ml) 
TX-IOO (2.5%) . 
. . 22 + 
Total amount of Na trapped 
Control 
401 (0.2 mg/ml) 
401 (0.1 mg/ml) 
TX-IOO (2.5%) 
22 .+ Total amount of Na trapped 
% 22Na+ leakage in 3h 
25.3 + 5.8 
37.5 .!. 2.83 
35.8 .!. 1.84 
83.6 .!. 3.88 
13 037 DPM 
4.6 .!. 0.51 
12.3 .!. 2.5 
7 .!. 0.45 
66.7 + 8.4 
35 605 DPM 
12.6 .!. 1.59 
17.62 .!. 1.6 
17 .!. 0.8 
54.6 + 8.8 
21 339 DPM 
each value is the average of three determinations 
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22 + . 
- Effect of peptide 401 on No. permeability 
ra.tes as a function· of the oholesterol/phospholipid 
ratio of the liposomes 
• 
• 
• 33 1.1 
ÕŸĤĤŸĤĤĤĤŸĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤĤŸĚcholesterol I phosphol ipid , 
401 .2mg/ml 
- - - - - -' 401 '.1 mgl ml 
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Although the liposomes made of PS alone were much more permeable to 
. . 
22 + Na , the effect of peptide 401 was more pronounced in the liposomes 
containing cholesterol, showing that besides the charge of the liposomes, 
the nature and the ratio between the lipids forming the liposomes seems 
to be important for the effect of peptide 401, concerning the increase 
22 + in permeability for Na and possibly its binding too. In Fig. 4-9 
the ratios between cholesterol and the phospholipids present in a 
preparation of liposomes were plotted against the ratios between the 
values of the 401 groups and controls of the experiments from Tables 
4-XI - 4-XIII and Figs. 4-6 - 4-8. This curve shows that there seems 
to be a correlation between the ratio cholesterol/phospholipid and the 
22 + 
effect of peptide 401 in increasing the permeability to Na. The 
highest effect is observed at a ratio 1.1, which according to Mahendra 
et ale (112) is when cholesterol is producing a maximum in 'packing' 
between the molecules forming the membranes, as reflected by a decrease 
in water permeability. 
4-4 Discussion 
The experiments carried out to investigate the binding of 
dansyl-401 to a population of human and rat blood cells demonstrated 
that red cells did not seem to interact with dansyl-401, whereas the 
leucocytes present in the blood did bind dansyl-401 as judged by intensity 
of fluorescence when observed under a UV microscope. It was not possible 
to distinguish among the leucocytes which cell type was binding d-401 
more strongly. However, in a population of cells obtained from the rat 
peritoneum, it could be seen that among mast cells, lymphocytes and 
macrophages, the affinity to d-401 was mast cells> lymphocytes) 
macrophages (see Plate 4-1). This is in agreement with the reported 
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effect of peptide 401 on degranulation of mast cells (31) and also with 
the results of G. Atkinson (11, 13) on histamine release induced by 
peptide 401, showing that rat mast cells are more sensitive to peptide 
401 than the rat polymorphonucleocytes. The results of the present 
experiments with d-401 support the suggestion put ȚŬŲŴŠŸTĚin the previous 
chapter on the possibility that peptide 401 was interacting 
preferentially with the rat leucocytes and inhibiting prostaglandin 
synthesis by those cells. However, it must be kept in mind that the 
alterations introduc.ed in the molecule of peptide 401 by the dansyl 
groups may be changing its in vivo properties. It was shown that the 
anti-inflammatory activity of peptide 401" treated with a 1:1 mol ratio 
401:dansyl, was reduced by approximately 1/3 (156) although its ability 
to degranulate mast cells was not very much altered. The experiments 
employing liposomes as ÜŸTŤŨĚmembrane systems were attempts to determine 
if a preferential binding between peptide 401 and the leucocytes could 
be explained by other features of the membranes beSides electric charge, 
since in vivo most tissues have a net negative charge at the physiological 
pH, due mainly to the sialic acid groups of the membrane glycoproteins. 
With this experimental model it was also possible to study such 
interactions using the intact molecule of 401. It was shown that no 
permeability effects due to 401 could be observed when glucose was 
trapped in liposomes made from lecithin and phosphatidic acid. On the 
22 + 
other hand when liposomes in which Na was trapped, were incubated with 
peptide 401 in concentrations of 0.1 mg/ml, an increased permeability 
22 + 
rate for Na was induced. This effect could be enhanced by varying 
the ratio cholesterol/phospholipid of the liposomes. The lack of lytiC 
effects on glucose liposomes with the same lipid composition as the 
22 + Na liposomes; together with an effect dependent on the cholesterol/ 
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phospholipid ratio, makes it improbable that the ability of peptide 401 
22 + to increase the permeability to Na derives from lytic effects on the 
membranes, as is shown to occur with melittin and polylysine (77, 154). 
Similar results have been reported for two brain specific 
proteins, which only affect the permeability rates to cations but not to 
glucose (33). In the present work, it could be argued that because 
glucose, an apolar solute, is able to permeate freely across the multi-
22 + lamellar structure of the liposomes, and Na, on the other hand, does 
not diffuse so easily, the permeability effect caused by peptide 401 in 
22 + the Na, liposomes was not necessarily due to any specific formation of 
"sodium channels". 22 + It is possible that in the case of the Na liposomes, 
peptide 401 was simply neutralizing negative charges on the membrane and 
22 + thus decreasing the opposing electrostatic barrier to Na. However, 
22 + the permeability effects of peptide 401 on the Na liposomes were 
shown to be dependent on the lipid composition of the membranes. When 
liposomes were made from nearly equimolecular concentrations of 
cholesterol and phosphatidyl serine this effect was more pronounced. 
Replacement of cholesterol by equal amounts of lecithin decreased the 
22 + peptide 401 induced Na permeability,' showing that this was not simply 
due to the presence of a neutral lipid component on the membrane. 
Moreover, liposomes prepared with phosphatidyl serine alone showed a 
22 + 
much greater spontaneous diffusion of Na, with a permeability effect 
caused by peptide 401 comparable with the ones found for liposomes with 
a phosphatidyl serine/lecithin ratio of 1.54. Although the 401 induced 
22 + 
, Na permeability could be partially explained by a simple decrease in 
22 + the electrostatic barrier for Na diffusion in some cases, as shown by 
the results in'Table 4-X, this clearly does not apply to-other experiments 
with 22Na+ liposomes. It appears then that the nature of the lipids, as 
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well as the ratios between the phospholipids and cholesterol of these 
22 + 
model membranes are important for the Na permeability effects of 
peptide 401. This effect of peptide 401 could have some implications 
in the mast cell degranulating activity of peptide 401. It was shown that 
degranulation of rat mast cells could be induced by means of ionophores 
++ 
which facilitate the penetration of Ca ions into the mast cells (68). 
As peptide 401 was shown to be able to degranulate mast cells in the 
++ 
absence of Ca ions, it was suggested that the histamine release by 
, 
mast cells, caused by peptide 401, could be mediated through an exchange 
+ 
of Na or· other cations (118, 13). In this caSe peptide 401 would be 
+ behaving as a Na ionophore. 
The results of the present experiments indicate that the 
22 + binding and Na permeability effect of 401 on liposomes may be directed 
by the cholesterol/phospholipid ratio of these membranes. If these 
results bear any relevance to the in vivo effects of peptide 401, how 
does cholesterol fit in this problem? The role of cholesterol in 
artificial membranes has been intensively studied recently. A number of 
experiments employing liposomes have shown that the presence of cholesterol 
is able to decrease the interaction between many cationic proteins and 
peptides with the liposomes (45, 128) and it has been suggested that 
cholesterol is able to do so by decreasing the 'fluidity' of the membrane. 
The concept of membrane fluidity (158) as applied to the cell membrane 
proposes that the protein sub-units as well as phospholipids are able to 
move freely on the two dimensional lipid fluid moiety of the membrane, 
the protein sub-units being hydrophobically bound to the lipids. The 
observed phenomenon of 'capping' (136) or migration of protein VẀŞŸẀŪÙWVĚ
to a certain point on the membrane prior to pinocytosis or mitosis is 
one example of this hypothesis. The role of cholesterol would be that 
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of decreasing the superficial motion of sub-units, and consequently 
causing a redistribution of charges on the cell membrane. The accepted 
idea is that cholesterol promotes a tighter packing of the phospholipids 
which increases the stability of the membrane probably by means of an 
increased interaction (hydrophobic) between the constituent lipids On the 
membrane (45). A number of metabolic activities inherent to the cell 
membrane seem to be dependent on the fluidity of the membrane (157). 
It has been reported recently that macrophages of rats fed on a cholesterol 
rich diet were not able to phagocyte as efficiently as the macrophages 
from control rats (58). The effect of cholesterol in decreasing membrane 
fluidity ŸŠVĚ led to the observation that the less metabolically active 
tissues seem to present a higher concentration of cholesterol as a 
membrane constituent (128). A similar situation appears to be occurring 
with the liposomes, as reflected by the few parameters which can be 
measured in these model membrane systems. Thus permeability rates for 
solutes, water permeability, and binding of basic proteins and peptides 
to liposomes are all decreased by incorporation of cholesterol in the 
membranes. 
In the present work, however, the permeability effects of 
peptide 401 On the liposomes were increased as a consequence of cholesterol 
incorporation in the membranes, in a ratio 1.1 cholesterol/phospholipid. 
The only reported case of similar effects caused by a basic protein was 
that of a basic myelin protein (128) which is able to induce increased 
solute permeability in liposomes independently of the cholesterol content 
of their membranes. It was suggested that such an effect was due to the 
'hydrophobicity' of this protein which has a high content of apolar amino 
acids in its molecule. Although peptide 401 does contain some apolar 
amino acids, it cannot be classified as a hydrophobic peptide. Moreover, 
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red cells from a number of different species have cholesterol/phospholipid 
ratios which are close to the value 0.9 (184, 121) and in the present 
work, liposomes with a cholesterol/phospholipid ratio of 1.1 were the most 
affected by peptide 401 although Plates 2 and 3 and Table 4-II show that 
there was no binding ŞŤWŴŸŤŪĚd-401 and the rat and human red cells. 
It has been concluded that apart from the lipids in the cell 
membranes the role of the proteins must be considered as well with respect 
. to the binding between peptide 401 and the leucocytes. It is possible 
that the binding of 401 to· the rat leucocytes depends on the sialic acid 
content of the membranes of these cells, in a way similar to that of 
the tetrapeptide tuftsin (36). The sialic acid content and the amount 
of cholesterol could then be TŤWŤŲÜÙŪÙŪŸĚ the VWŲŸȘWẀŲŠŨĚfeatures of the 
membranes on which the interaction of peptide 401 would be dependent. 
Differences in the sialic acid content of the several tissues of the rat 
are to be expected, although there are no data on the sialic acid" 
composition of the rat polymorphonucleocytes (120) •. 
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CHApTER 5 
PEPTIDE 401 AND CORTICOSTERONE SYNTHESIS AND RELEASE 
5-1 Introduction 
5-1-1 Occurrence and biosynthesis 
The adrenal steroid hormones are synthesized and secreted by 
t'he cells of the zona glomerulosa, fasciculata and reticularis of the 
adrenal cortex. The main precursor of the adrenal corticosteroid 
hormones is cholesterol. The biosynthetic pathway of some of the 
corticosteroids is summarized below. The steroid hormones are 
synthesized and released as a consequence of the action of ACTH 
(adrenocorticotropic hormone). ACTH is a polypeptide hormone synthesized 
by the adenohypophysis. The adrenal cortex is not innervated and ACTH is 
believed to be the major controlling agent for synthesis and release of 
the steroid hormones by the adrenal cortex. The steroid hormones are 
f 
not stored in the cells and sO ACTH action must involve de novo synthesis 
of the hormones (170). It is believed that the corticosteroid-genesis 
induced by ACTH is mediated by stimulation of adenyl cyclase and hence 
intracellular formation of cyclic AMP (153). 
5-1-2 Hormonal action of corticosteroids 
The corticosteroid hormones are classified according to their 
physiological role. Thus the mineralocortocoids influence the electrolyte 
balance of the organism, and the glucocorticoids control most reactions 
of the carbohydrate and protein metabolism. Another class of adrenal 
corticosteroids include the sex hormones, which control the secondary 
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sexual characters, but the 'adrenal glands are not very important concerning 
the production of these hormones. 
5-1-3 Anti-inflammatory activity 
Apart from their actions on the parbohydrate and protein 
metabolism the glucocorticoids are very potent anti-inflammatory agents 
(84). The glucocorticoids are able to act either locally or systemically 
suppressing erythema, oedema, heat and local increased vascular 
permeability. However as anti-inflammatory agents their therepeutic 
action is limited due to the number of side effects produced. Thus a 
long-term treatment with glucocorticoids can lead to interference with 
the pituitary-adrenal relationship, imbalances on the electrolyte 
composition of the several fluids, osteoporosis and decreased resistance 
to infections since glucocorticoids have immunosuppressive effects (170), 
ÙŸŤĦĚ they inhibit antibody production,apart from causing the disappearance 
of cells whichare normally engaged in phagocytosis and digestion of 
foreign compounds and bacteria. The anti-inflammatory activity of the 
glucocorticoids is poorly understood. There have been attempts to 
establish a direct correlation between the action of the glucocorticoids 
on carbohydrate metabolism and their anti-inflammatory effects, but no 
clear picture has emerged (71). 
5-1-4 Action on membranes 
It has been proposed that the anti-inflammatory effects of 
steroid hormones are a result of their direct action on the membranes 
of lysosomes (186), making them more stable, i.e., not susceptible to 
lysis. Lysosomal enzymes.which are usually responsible for many of the 
manifestations of inflammation are consequently not released. The work 
of Baugham et ale (15) using liposomes as model membranes supported this 
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view since steroid hormones and cholesterol have stabilizing effects on 
the lipid membranes (see also Chapter 4). However, recent work on the 
anti-inflammatory activity of glucocorticosteroids suggests that 
inhibitory effects on the ÜŤWŠŸŬŨÙVÜĚof leucocytes may be more important 
{ 
than a direct action on the lysosomal membranes. Thus, by depressing 
several metabolic pathways the stimuli for lysosome fusion with the· 
cytoplasm membrane would be blocked (132) •. 
5-1-5 Action on cell migration 
The anti-inflammatory action of ŦŨẀŸŬȘŬŲWÙȘŬÙTVĚcan also be 
related to the disappearance of cells that normally participate in the 
inflammatory process. It has been shown that glucocorticoids decrease 
. 
the number of monocytes present in the circulation during inflammation 
(171), although this action is also evident in rheumatoid arthritis 
where neutrophiles seem to predominate. Glucocorticoids are able to 
decrease the sticking of leucocytes to the vascular endothelium and to 
decrease the migration of monocytes across the basement membrane (171). 
The direct cytotoxic effect of lymphocytes is also suppressed by 
glucocorticoids although the lymphocytes retain their ability to adhere 
to the foreign cells (141). 
5-1-6 Peptide 401 and stimulation of corticosteroid synthesis 
The possibility therefore that peptide 401 can derive part of 
its anti-inflammatory effect by stimulating production and release of 
corticosteroids has to be considered. The slight reduction in the anti-
inflammatory activity of peptide 401 when injected into adrenalectomized 
rats, suggests that part of its activity might be mediated by the ŸĚ
'2.7 , Sf 
corticosteroids ĜŸHĚre&). Furthermore, it was shown that when whole 
bee venom as well as some impure fractions of the venom that might have 
contained peptide 401 are injected into rats, the corticosterone levels 
in the serum rise to values that could definitely produce anti-
inflammatory effects (38, 202). It has been suggested that the 
therapeutic effect of the bee venom in the'rat adjuvant,arthritis is a 
consequence of this increased formation of corticosterone (Ill). 
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However, the problem of assaying corticosteroids in vivo is 
difficult because of the stress involved in the experimental conditions. 
Apart from the variations of the serum corticosteroids associated with 
the normal circadian rhythm of the animals studied, handling and 
injections of test substances into the animals are per se non-specific 
inducers of corticosteroid formation. For example, injection of isotonic 
saline into rats has been observed to increase the level of serum 
corticosterone. With bee venom, this problem is further complicated by 
the ability of VŤẂŤŲŸŨĚfractions of the venom to induce histamine 
release which itself is able to induce corticosteroid formation (38, 151). 
In order to aVOid, therefore, the TÙȚȚÙȘẀŸWÙŤVĚin interpreting the 
results of in vivo experiments, the present work was carried out using 
an in vitro system. In the rat corticosterone is the main steroid 
hormone secreted by the adrenal cortex (178). 
5-2 Experimental 
5-2-1 Materials 
The incubation medium for the rat adrenal glands, RPMI 1640, 
. foetal calf serum, glutamine, triptose phosphate broth and the plastiC 
tissue culture dishes, were obtained from Gibco Biocult. Dichloromethane 
(Hopkin and Williams) was washed with 10% sulphuric aCid, 4 times with 
distilled water, dried overnight over CaC1 2 and distilled through a 
Vigreux column. Absolute ethanol (James Burrough Ltd.) was refluxed 
for 2 h with 5 g of 1,2,4-dinitrophenylhidrazine and 10 ml of 
concentrated HCI. It was then distilled twice through a Vigreux column. 
Sulphuric acid was boiled for 3 h. Anhydrous sodium sulphate was 
obtained from Fisons Laboratory Reagents. Corticosterone, collagenase 
(Type I), ACTH (adrenocorticotropic hormone, porcine, grade II, 88 i.u./ 
mg) and deoxyribonuclease Type I were obtained from Sigma Chemical Co. 
All the surgical tools and glassware used for the collection and 
'incubation of the rat adrenal glands were sterile. 
5-2-2 Collection and incubation of adrenal glands 
Male rats (wistar) were killed with a blow on the head and the 
adrenal glands removed as quickly as possible and placed in chilled PBS, 
pH 7.4 until used. The glands were then washed with RPMI, freed from 
fat and quartered using scalpels. The pieces were then placed on tissue 
culture dishes as described in the diagram below. 
Adrenal Stainless steel BTid covered ŸŪWUĚ
lens tissue 
RPM I medium 
paper ring moistened with water 
The RPMI medium with the test substances was added to the centre well 
until it just touched the gland pieces thus forming a film over them. 
The dishes were placed inside dessicators half filled with sterile 
distilled water and then a gas mixture consisting of 95% 02' and 5% CO 2 
was bubbled through the,water for 20 min. The closed dessicators were 
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then incubated at'37 C for the required amount of time. After incubation, 
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the medium in the centre well was collected by means of sterile syringes 
and the corticosterone present was extracted and assayed. The pieces 
of the adrenal glands of each dish were then immersed in acetone and in 
absolute ethanol, dried and weighed. 
5-2-3 'Cell dispersions 
The method used to obtain cell dispersions from rat adrenal 
glands was based on that of Falke et ale (56). After killing the rats 
as described before, the adrenal glands were removed and placed in cold 
PBS, pH 7.4 until used. The glands were then trimmed of fat and each 
one was cut into 6-8 pieces. The pieces from every 10 glands were 
pooled together in a 25 ml conical flask and to this 5 ml of the RPMI 
medium containing 5 mg/ml collagenase ŠŸTĚ0.5 mg/ml DNAase was added. 
The reason for adding DNAase 'was to prevent sticking of ŸŤŨŨVĚ to DNA 
released from dead cells. The flasks were then placed in a water bath 
at 37°C and incubated for 20 min with constant agitation and gassing 
(95% O2 + 5% CO 2). After this incubation the supernatant was collected 
. ° with a Pasteur pipette and placed in a container at 0 e. The incubation 
with collagenase and DNAase was repeated two more times. After the last 
incubation, the remaining pieces were sucked and discharged repeatedly with 
a Pasteur pipette in order to disperse the remaining tissue. The bigger 
particles were then discarded. The cell suspension was then lett to 
stand for 5 min at oOe and the heavy sediment discarded'too. The cell 
" 
suspension was then washed three times with enzyme-free RPMI, using a 
refrigerated centrifuge at 100 g for 10 min each time. The cell pellet 
was then gently resuspended in a fresh medium (RPMI) and counted in a 
, . 
haemocytometer. The cell count was usually between 200,000-600,000 cells/ 
ml. From this cell suspension, aliquots of 0.5 ml were incubated with 
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the substances being tested which were ŸÙVVŬÍẂŤTĚin 0.5 m1 of the RPMI 
medium. Incubation was carried out as described in the diagram below 
o . 
for 2 h at 37 C with constant agitation. 
ŸŪGŨĚ ŸŅĚ
ŸĚ ŸĚ ŸĚ
The blanks were obtained by sonicating the cells prior to incubation. 
After the incubation the cells were centrifuged and aliquots of 0.5 ml 
from the supernatant were collected and the steroids extracted and 
assayed. Alternatively, the total contents of the incubation tubes were 
extracted. 
5-2-4 Extraction and assay of corticosterone 
This was done according to the method of De Langen et al.(44). 
The aliquots obtained from both the tissue culture and cell dispersion 
experiments were extracted directly with 10 ml of dichloromethane. After 
decanting the aqueous phase, the dichloromethane was poured into tubes 
containing 1 g of anhydrous Na2S0 4, stirred and left standing at 4°C 
overnight. Standard solutions of known amounts of corticosterone were 
treated in the same way. From these solutions, aliquots were collected 
and added to the fluorescent reagent which consisted of 25 ml of 
concentrated H2S0 4 + 10 ml of 75% ethanol. The ratio between the 
aliquots of the extract and the fluorescent reagent was 1.5. The 
mechanism by which corticosteroids fluoresce in the presence of 
concentrated H2S0 4 is poorly understood. When steroidal 17 ,alkyl,-
17 -hydroxy-4,6,-dien-3-ones, are treated with concentrated sulphuric 
acid, the following reaction occurs that probably applies for cortico-
sterone ŠVŴŤŨŨŸGŸGĞĔĚ
... H 
o 
o 
Ethanol is added to solubilize the steroids. 
The tubes containing aliquots of the dichloromethane extracts 
and the fluorescent reagent were then stirred and left to stand at room 
temperature for 30 min. Prior to measuring the fluorescence intensity, 
the tubes were stirred again. A fresh ŸŨẀŬŲŤVȘŤŪWĚ reagent was prepared 
for every experiment. The fluorescence intensity of the aliquots was 
measured in a Perkin-Elmer fluorescence spectrophotometer model MPF-3, 
using an excitation wavelength of 466 nm and emission wavelength of 
520 nm. These two values for wavelength were obtained after scanning a 
sample of corticosterone prepared as described above. 
5-3 Results 
5-3-1 Quartered glands 
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Table 5-I and Fig. '5-1 show the results of incubating the 
quartered adrenal glands in the presence and absence of ACTH (0.1 mu/ml) 
\ 
at 37°C and at 4°C, for several intervals of time. The results are 
expressed in ng of corticosterone produced per 100 mg of tissue. For 
every experiment a standard curve plotting corticosterone concentration 
against fluorescence intensity ,was made. From these ȘẀŸẂŤVHĚ the values 
of each point were calculated. 
Table 5-I 
Effect of ACTH on corticosterone production by 
quartered adrenal glands at 37°C and 4°C 
ng corticosterone ng corticosterone 
in 100 mg in 100 mg 
37°C 4°C 
Control 1 h 62.4 20.1 
" 
5 h . 128.8 25.1 
" 
20 h 341 27.6 
ACTH 1 h 69.2 28.3 
" 
5 h 140.1 35.8 
" 
20 h 450 29.9 
At every time interval of the results above, the medium bathing the 
adrenal pieces was collected and replaced by a fresh one with the same 
components. The gassing was also repeated. 
The results of experiments where the quartered adrenal glands 
° were incubated for 5 h at 37 C with several concentrations of ACTH are 
presented in Table 5-II and Fig. 5-2. 
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Table 5-II 
Effect of several concentrations of ACTII on cortico-
sterone production by.quartered.adrenal glands. 
Control 
ACTH (0.156 mu/ml) 
" 
(0.312 mu/ml) 
" 
(0.625 mu/ml) 
" 
(1.25 mu/ml) 
ŸŦĚcorticosterone in 
100 mg of tissue 
0.293 
0.782 
1.536 
1.567 
1.866 
each value represents the average of two determinations 
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Table 5-III ana Fig. 5-3 show the results of experiments where 
. . 0 
quartered adrenals were incubated for 5 h at 37 C with ACTH and peptide 
401. Peptide 401 was incubated in concentrations of 1 and 10 ŸŦIÜÍĦĚ
Table 5-III 
Effect of peptide 401 and ACTH on corticosterone 
production by quartered adrenal glands 
ŸŦĚcorticosterone 
100 mg of tissue 
Control 5.52 
ACTH "312 mu/ml) 15.75 
" . (2.5 mu/ml) 12.38 
401 (1 ŸŦIÜŨĞĚ 0.38 ŸÓĚ 24.39 
" 
(10 ŸŦIÜŨĞĚ 38 ĦŸÓĚ 16.7 
each value is .. the .av:erage_ of two .determinations 
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FI G 5-2 - Effect of ACTH on corticosterone synthesis 
and release by quartered adrenal glands. 
(data from Table 5-II) 
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Although the above results "indicate that peptide 401 stimulates the 
synthesis of corticosterone, the previous control experiments (Table 
5-II, Fig. 5-2) could not be reproduced. When these experimental 
conditions were repeated, the ŸŨŠŪTVĚ frequently did not respond to ACTH 
and when they did, the dose response curve'was never coherent. The 
amount of corticosterone present in the medium bathing the glands varied 
too much and the irreproducibility was such that no conclusions could be 
drawn. This behaviour is caused by the difficulty of oxygen and the 
\ nutrients present in the medium to reach the inner regions of the glands. 
The adrenal cortex is normally highly vascularized and in the present 
culture conditions, only the outer surfaces are bathed by the medium. 
Likewise, the formed corticosteroids are not able to diffuse freely out 
of the tissue and may a?cumulate inside thus influencing the metabolical 
state of the adrenal cells (56). For this reason, the method of 
quartered adrenal glands was replaced by cell dispersions of adrenal 
glands. 
5-3-2 Cell dispersions 
The standard curve obtained by plotting the corticosterone 
concentration against the fluorescence intenSity, after treatment with 
the fluorescent reagent is presented in Fig. 5-4. The curve in Fig. 5-4 
was .obtained by adding known amounts of corticosterone to a cell 
dispersion of rat adrenal glands. The equation derived from this curve is 
y = -25.75 + 20.71 x 
where y = ng corticosterone 
x = fluorescence intenSity. 
This equation was applied ·to calculate the concentration of corticosterone 
in all samples from the cell dispersion experiments. 
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FIG 5-4 - Standard concentration - fluorescence intensity 
curve for corticosterone treated with 
concentrated H2S04 
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Figs. S-S and 5-6 show typical prepar atj,ons of c ells from 
adrenals obtained in the present work. 
. . 
Ta ble S-IV shows the amount of corticost erone formed as a function of 
number of cells obtained from ŸŠWĚa drenals, incubated in the absence of 
ACTH. 
Tabl e S-IV 
Corticost erone production by adrenal cell dispersions -in the absence of ACTH 
No. c e11s/m1 ng corticosterone 
172 sao ( 2) a 
19S 000 ( 2) 1 .• 79 
416 000 ( 2) 12.56 
660 000 (3) 14.84 
The numb er between parenthesis indicates the number 
of experiments 
It can be seen that a lthough th e unstimulated cello produc e very little 
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corticosterone (which is in agreement with the results of Falke at al. 
(56), there is a direct correlation between the number of cells present 
in the incubation medium and the amount of corticosterone produced. 
Table 5-V shows the results of incubating the adrenal cell dispersions 
with several concentrations of ACTH and peptide 401. The results are 
expressed as ng corticosterone/ml/h. 
Table 5-V 
Effect of peptide 401 and ACTH on .corticosterone .production by adrenal cells 
Blank 
Control 
ACTH (.01 mu/ml) 
" (.1 mu/ml) 
" (1 mu/ml) 
401 (.005 ŸŦIÜŨĞĚ 0.0019 ŸÓĚ
II (.05 ŸŦIÜŨĞĚ 0.019 ŸÓĚ
" (.5 ŸŦIÜŨĞĚ 0.19 ŸÓĚ
Corticosterone 
(ng/ml/h) 
o 
1.79 
o 
8.42 
150.6 
o 
o 
each value is the .average-of two determinations. 
It can be seen that only concentrations of peptide 401 of .5 ŸŦIÜŨĚ
elicit some corticosterone production; however, this amount is not 
much higher than the amount produced by the control cells. In another 
set of experiments peptide 401 was incubated with the adrenal cell 
dispersions in higher concentrations. The results are presented in 
Table 5-VI and Fig. 5-7. 
Table '5:"'V! 
Effect of peptide 401 and ACTH on corticosterone production by adrenal 
cell .d.ispersions "'- .. - -"-' " 
Control 
ACTH .01 mu/ml 
" 
.1 mu/ml 
" 
1 mu/ml 
401 .1 Ilg/ml 
401 1 Ilg/ml 
401 10 jlg/ml 
0.038 11M 
0.38 11M 
3.8 jlM 
ng corticosterone/ml/h 
6.28 
7.31 
20.77 
530.5 
2.65 
4.21 
2.65 
It can be seen that although the cells were responding to ACTH, peptide 
401 failed to significantly induce an increased formation of cortico-
sterone. The results of similar experiments, but with higher 
concentrations ot peptide 401 are presented in Tabie 5-VII. 
Table 5-VII 
Effect of peptide 401 and ACTH on corticosterone production by adrenal 
.. cell. dispersions ., 
ng corticosterone/ml/h 
Control 7.48 .!. ÌŸĬĚ
ACTH 1 mu/ml 361.25 .!. 144 
401 1 Ilg/ml 0.38 jlM 6.44 .!. 1.58 
401 10 Ilg/ml ĨĦŸĚ 11M 5.75 .!. 1.78 
401 100 Ilg/ml 38 11M 5.41 .!. 2.6 
each value ŸVĚthe ŸẂŤŲŠŦŤĦŬȚĚ.. thvee TŤWŤŸÜÙŪŠWŨŬŪVĚ
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(data from Table 5-VI) 
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The above results show that adrenal cells incubated with peptide 401 
up to concentrations of 100 ŸŦIÜÍHĚ fail to have any influence on the 
corticosterone product1on. 
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As there are a number of reports where injections of whole bee 
venom into rats induced an increased formation of cortiqosterone (38, 
202), another set of experiments was carried out in which the whole 
venom, the fraction containing the low molecular weight components of 
the venom and the fraction containing the high molecular weight 
components were incubated with the adrenal cell 
results are presented in Table 5-VIII. 
Table 5-VIII 
dispersions. The 
Effect of several bee venom fractions and ACTH on corticosterone production 
. by adrenal cells 
Control 
ACTH 1 mu/ml 
Whole bee venOm (0.1 mg/ml) 
Low mol. weight (0.1 mg/ml) 
High mol. weight ( 
" 
) 
ng corticosterone/ml/h 
o 
295.1 
o 
o 
o 
each value is the average of two determinations 
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5-4 Discussion 
The present experiments show that peptide 401 in a concentration 
range of .005 - 100 ŸŦIÜŨĚdoes not induce increased corticosterone 
formation when incubated with cell dispersions obtained from rat adrenal 
glands. When peptide 401 was incubated ŴŸWUĚquartered adrenal glands a 
single experiment showed that peptide 401 in a concentration of 1 ŸŦIÜŨĚ
was able to induce corticosterone formation with values of approximately 
5 times over the controls. This might mean that some integrity in the 
gland is required for peptide 401 activity. However, it is not possible 
to draw any conclusions from the experiments using the quartered glands 
since the results of several other experiments were not reproducible, 
with much scattering among them, and it was not possible also to· establish 
a dose response curve for ACTH. The reasons for such erratic behaviour 
were already commented on in section 5-3. 
Although the cell dispersions lack the tissue organization of 
the quartered glands, corticosteroidogenesis could be induced by ACTH in 
concentrations which are normally found in the rat blood after 
inflammatory stimuli (153), showing that the precursors for the synthesis 
of corticosteroids were available and that all the systems involved in 
the biosynthesis of the corticosteroids were intact. Thus it can be 
concluded that peptide 401 does not have a direct action on the adrenal 
cells as happens with ACTH. The other fractions present in the bee 
venom also tailed to have any influence on corticosterone production in 
the single dose tested of 0.1 mg/ml. However, this does not rule out the 
possibility that peptide 401, like the other bee venom fractions tested 
in vivo, can stimulate corticosteroid formation indirectly. For instance, 
it has been shown that histamine is able to stimulate production of 
corticosteroids (38, 151). Since peptide 401, like other peptides 
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present in the bee venom, is able to induce histamine release, this 
could constitute a way for indirect action on the adrenals. If such was 
the case, however, the anti-inflammatory activity of peptide 401 would 
only be transient and occurring only at concentrations of peptide 401 
which are able to produce systemic inflammatory effects in the rat. 
The optimum dose of peptide 401 for anti-inflammatory activity would be 
expected to induce histamine release only at the site of inoculation. 
Furthermore, pre-treatment of the rats with antagonists of histamine 
and serotonin does not suppress the anti-inflammatory activity of peptide 
401 (81, 27). Presumably, the slight reduction in the anti-inflammatory 
activity of peptide 401 in adrenalectomized rats is reflecting precisely 
this histamine mediated effect. 
Alternatively peptide 401 can have ŸŪĚin vivo stimulatory 
effect on the adenohypophysis with a resulting increased formation of 
ACTH. This seems to be· occurring with the whole bee venom. The 
experiments of Alfano et ale (2) .show that the bee venom is not able to 
. / 
induce corticosterone formation in hypophysectomized rats. It should be 
worthwhile to test the ability of peptide 401 to influence the production 
of ACTH using a similar experimental approach as in this chapter. 
In conclusion, the fact that the anti-inflammatory activity of 
peptide 401 persists in adrenalectomized rats and that peptide 401 fails 
to.induce corticosterone production by rat adrenal cell dispersions makes 
it improbable that the anti-inflammatory activity of peptide 401 is 
mediated by corticosteroids. 
ĤĤĤĤĤĤĤĴĤĤĤĤĤĤĤĤĤĤĤĤĤĤŸĦĤĤĤĤĦĤĤĤĤĤĤĤĤŸĤĤ.. -.-----
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CHAPTER- 6 
PEPTIDE 401 AND MATURATION OF LYMPHOCYTES 
6-1 Introduction 
6-1-1 Lymphocytes in rheumatoid arthritis 
Peptide 401 was shown to have anti-inflammatory activity in 
induced adjuvant arthritis in the rat (27). One of the characteristics 
of this animal model is that the chronic inflammatory arthritis can be 
passively transferred by viable lymphoid cells, but not by serum (131, 
180). This suggests that a cell mediated immune process is involved. 
In man,rheumatoid arthritis was first thought to be due almost entirely 
to a humoral component, i.e., to the presence of immune complexes that 
are known to activate the complement system and produce chemotactic 
substances for polymorphonucleocytes (204), and probably other 
inflammatory cells. However, the occurrence of rheumatoid arthritis in 
agammaglobulinaemic patients (143) and the presenCe in the lesions of 
large numbers of lymphocytes other than plasma cells, suggested that 
these cells might play a role in the maintenance of this chronic 
inflammatory state (123). 
The actions of the lymphocytes might be mediated by a direct 
cytotoxic effect towards the synovial cells (133). I'n addition, those 
actions might be mediated by lymphokine-s, which are substances synthesized 
by sensitized lymphocytes and capable of various activities that would 
help to perpetuate the inflammatory state. These activities include 
vasodilatation, accumulation of macrophages and proliferation and 
differentiation of lymphocytes (53). Supporting this notion is the 
ĤĤŸĤĤĤĤĤĤĤĤĤĤŸĤŸĤĤĤĤĤĤĤĤĤŸĤĤĤĤĤĤŸĚ
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finding that lymphokine-like materials have been found in the synovial 
fluid of patients with rheumatoid arthritis and in some patients with 
other forms of chronic inflammatory arthritis (164). To stress the role 
played by lymphocytes, it was shown that in lymphocyte depletion 
experiments in man (130) and in rats (43) an amelioration of the arthritic 
condition could be oboerved. 
6-1-2 Lymphocyte activation 
Secretion of biologically active materials as well as 
transformation into an effector cell depends on lymphocyte activation. 
Lymphocyte activation refers to a series of morphological and biochemical 
changes that accompany the transformation of a small lymphocyte into a 
blast cell after contact with antigen. This mayor may not lead to 
cell division, but the increased incorporation of 3H-thymidine into the 
cell DNA has been used as one of the parameters indicating lymphocyte 
. activation. Some of the possible actions of anti-inflammatory drugs in 
chronic arthritic conditions might arise from inhibition of lymphocyte 
migration to the site of inflammation and/or interference with lymphocyte 
activation resulting in a decreased production of lymphokines and 
cytotoxiC lymphocytes. In fact, experiments with non-steroidal anti-
inflammatory agents have shown that this may be the case. Aspirin and 
indomethacin are able to inhibit in vitro the amoeboid movements of 
lymphocytes induced by ATP (76). These movements are believed to be 
assOCia,ted with the capacity to migrate across the endothelium of the 
blood vessels during inflammation. The same drugs were also shown to 
inhibit the direct cytotoxic effects of lymphocytes in an experimental 
tumour model (197). Furthermore, salicylate is capable of inhibiting 
3 in vitro protein synthesis and H-thymidine ÙŸȘŬŲŮŬŲŠWÙŬŪĚby lymphocytes, 
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reflecting an impairment of lymphocyte activation (126, 67). Suppression 
of lymphocyte transformation was also observed in vitro after aspirin 
administration (40). 
6-1-3 Peptide 401 and lymphocyte activation 
In Chapter 4 it was shown that d-401 was able to bind to rat 
• lymphocytes and therefore the possibility exists that peptide 401 can 
exert its anti-inflammatory effects in the rat adjuvant arthritis throu.gh 
an action On lymphocytes. This was investigated in the present 
experiments by measuring the influence of peptide 401 on the incorporation 
of 3H-thymidine by lymphocytes in the presence and absence of phyto-
haemaglutinin (PHA). PHA is a lectin isolated from the bean Phaseolus 
vulgaris which is capable of inducing lymphocyte activation in a way 
which closely resembles the reaction between antigen and sensitized 
lymphocytes (79), a situation which supposedly occurs in the rat adjuvant 
arthritis. 
6-2 Experimental 
6-2-1 Materials 
The animals used were wistar rats (3 months old) obtained 
from the Wright Fleming Institute, St. Mary's Hospital Medical School. 
The tissue culture medium, RPMI 1640 was obtained from Flow Laboratories. 
This medium was supplemented with HEPES buffer, ŨȘÖŸĚfoetal calf serum 
and the antibiotics penicillin (100 ŸŦIÜŨĞĚ and streptomycin (100 ŸŦIÜŨĞHĚ
also from Flow Laboratories. The culture microtest plates, with flat 
bottom were obtained from NUNC, cat. no. 1480. PHA (phytohaemagglutinin), 
reagent grade, was obtained from Wellcome Research Laboratories, and was 
dissolved in 5 ml of distilled water to give a stock solution of 10 mg/ml. 
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This was stored at 40 C and diluted with RPMI to the required concentration 
when used. 
Prostaglandin El was a gift from Dr. J.E. Pike (The Upjohn 
Laboratories). PGEI was dissolved in a few drops of ethanol and this 
was diluted to the required concentration with the RPMI medium. This 
solution was filtered through a Milipore membrane (0.45 ŸĚ pore size) 
in order to sterilize it. 
Peptide 401 was diluted in the RPMI medium and also filtered 
as described above prior to use. Methyl 3H-thymidine (5 ci/mM) was 
obtained from the Radiochemical Centre, Amersham. 3 Methyl H-thymidine 
was diluted with RPMI to give a final concentration of 1 ŸȘÙĚper culture. 
The scintillation fluid consisted of a solution of toluene containing 
6 g / 100 ml PPO and 12 mg / 100 ml of POPOP. The filter paper, grade 
3 MM, size 1.9 cm was obtained from Whatman. 
Lymphocyte culture technigue 
The animals were killed by cervical dislocation and the 
mesenteric lymph nodes were used as the source of lymphocytes. The 
cell suspension was obtained by teasing the lymph node with syringe 
needles and pressing the cells through a metal sieve with the aid of a 
plunger obtained from sterile disposable syringes. The tissue remaining 
on the metal sieve was repeatedly washed with the RPMI medium during 
the teasing procedure. 
. . 
The cell clumps were allowed to sediment and the 
supernatant 'transferred to a sterile disposable universal with a conical 
bottom. This was then centrifuged for 5 min at 300 g in a bench type 
centrifuge, at room temperature. The cells were washed once, resuspended, 
and counted in a haemocytometer. Cell viability was assessed using phase 
contrast microscopy and the final cell suspension was adjusted to a 
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6 density of 5 x 10 cells/mI. 
Replicate cultures were set up in the microplates with 200 ŸŨĚ
of the cell suspension for each well. The microplates were placed inside 
a dessicator and gassed with 5% CO 2 in air. The dessicator was kept in 
an incubator at 37 0 C for 48 h. The drugs being tested were added at 
the beginning of the culture period and left during the whole incubation 
time. 
6-2-3 Assessment of the mitogenic response 
This was done through cellular incorporation of 3H-thymidine 
into intracellular DNA precipitated by trichloroacetic acid (TCA). 
3H-thymidine was added to each well 24 h after the cells were put in 
culture conditions. After another 24 h the microplates were cooled in 
ice and 100 ŸŨĚaliquots were collected and left to dry in filter paper 
discs mounted in pins. The filters were subsequently transferred to a 
beaker, washed three times with a cold ŨŸĚsolution of TCA (w/v) and 
twice in cold methanol. The discs were then transferred to scintillation 
vials, allowed to dry and then counted in a Packard liquid SCintillation 
spectrometer, with 5 ml of the scintillation fluid. 
Viability test 
In order to test if peptide 401 itself had any cytotoxic 
effects on the rat lymphocytes and on rat leucocytes obtained from a 
peritoneum exudate, a fluorochromatic test, based on that of Rotman et ale 
(142), was carried out. The method consisted of incubating the cell 
suspension (in the RPMI medium) with peptide 401 in several concentrations 
o 
and time intervals, at 37 'C and then adding to the suspension fluorescein 
diacetate (FDA). Esterases present on the cell membrane react with FDA 
154 
and form free fluorescein, which does not diffuse out of the cells as 
quickly as FDA penetrates into the cytoplasm (142). Therefore it is 
possible to measure the rate of increase in fluorescence intensity as a 
consequence of intracellular accumulation of fluorescein. The mechanism 
whereby fluorescein accumulates intracellularly, though not known, is 
dependent upon cell integrity. 
In the present work, the rate of increase in fluorescence 
. intensity was measured using a Perkin-Elmer MPF-3 fluorescence spectro-
photometer equipped with a thermostated cell holder, using an excitation 
wavelength of 490 nm and emission of 516 nm. The cell suspensions were 
incubated at 370 C in the spectrofluorimeter with the compounds being 
tested, and after the required time FDA in a final concentration of 
5 ŸŦIÜŨĚwas added to the medium and the rate of increase in fluorescence 
was recorded. FDA was dissolved with a few drops of acetone and then 
diluted to the required concentration with the RPMI medium. 
6-3 Results 
Lymphocyte activation and peptide 401 
The results of the experiments measuring the effect of peptide 
3 401 on the H-thymidine incorporation by lymphocytes in the presenCe 
and absence of PHA are presented in Table 6-1. 
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Table 6-1 
Effect of peptide 401 on lymphocyte activation in the absence and presence 
of PHA 
EXP 1 
NO PHA PHA {10 l!e!mU 
No •. of No.of 
experiments CPM experiments CPM 
(3) Control 1632':234 (4) 6461,:851 
(4) 401 (100Ilg!ml) 1281,:190 (4) 5003.:539 
(4) 401 (10Ilg/ml) 2012:.211 (4) 5688:.561 
(4) 401 (1Ilg!m1) 2181:.399 (4) 5576.:427 
(4) PGE1 (10-4M) 516:'40 (4) 1154.:63 
PGE1 (10-4M) + 401 (4) 1266,.:263 (100 Ilg/ml) 
EXP 2 
(4) Control 848:.71 (4) 3677.:324 
(4) 401 (100Ilg/m1) 640:.49 (4) 2855,.:414 
(4) 401 (1-jlg/m1) 1148,:111 (4) 3759,:171 
(4) 401 (1Ilg/m1) 996,:78 (4) 3353,:241 
(4) 401 (0.5Ilg/m1) 10521 275 (4) 3391":550 
(4) PGE1 (10-4M) 417175 (4) 296!,27 
(4) PGE1(10-4M) +401 (100jlg/m1) 346,:10 (4) 336!,9 
(4) PGE1(10-4M)+401(10Ilg!m1) 378!,33 (4) 428!,20 
(4) PGE1(10-4M) +401 (1Ilg/m1) 367!,133 (4) 401!,8 
(4) PGE1(10-4M)+401(0.Sllg/m1) 397:'59 (4) 34S!,43 
3 In order to establish if the effect of peptide 401 on the H-thymidine 
incorporation by the lymphocytes was significant, the individual results 
of the experiments where peptide 401 was incubated with the cells in 
concentrations of 100 and 10 Ilg/ml were pooled and used in the students' 
t test. The values for P were the following: 
a) differences between the results of the control group (n=7) and 
peptide 401 (100 ŸŦIÜŨĞĚ (n=8), in the absence of PHA 
t = 2.88, corresponding to 
.02.( P <: .01 
b) differences between the values of control group (n=7) and peptide 
401 (10 ŸŦIÜŨĞĚ (n=8), in the absence of PHA 
t - 1.69, 
.2< P . (.1 
corresponding to 
c'> differences between the control group (n=8) and peptide 401 (100 
ŸŦIÜŨĞĚ (n=8) group, in the .presence of PHA (10 ŸŦIÜŨĞĚ
t - 1.59, 
.2<: ÖŸĦŨĚ
corresponding to 
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d) differences between the control group (n=8) 'and peptide 401 (10 ŸŦIÜŨĞĚ
(n=8) group in the presence of PHA (10 ŸŦIÜŨĞĚ
t . = .501, 
.7<::PL..6 
corresponding to 
The significance of the results of experiments where peptide 401 was 
incubated in concentrations smaller than 10 ŸŦIÜŨĚwas not calculated 
since the values of these groups were very close to the respective 
controls. 
Viability tests 
The results of the cytotoxicity of peptide 401 on the rat 
mesenteric lymphocytes are presented in Table 6-1I. 
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Table 6-II 
Effect of peptide 401 and melittin on.cell viability 
4 h 22 11 
F.I. F.I. 
(2 min after 
adding FDA) . 
Control 51.5 58.5 
401 (1.25 mg/ml) 61.5 36.5 
401 (0.625 mg/ml) 40.5 40.5 
401 (0.125 mg/ml) 55.5 33.5 
401 . (0.0625 mg/ml) 44.5 34 
Melittin (0.5 mg/ml) 31 32 
Control cells kept in ice 96 78 
The results in Table 6-II show that peptide 401 in concentration of 
0.125 mg/ml has some cytotoxic effects On the lymphocytes after incubation 
for 22 h whereas no effects are apparent after 4 h. The same test was 
carried out with cells obtained from the rat peritoneum exudate. The 
o 
cells were pre-incubated for 1 h at 37 C with the compounds being tested 
and then FDA was added to the medium. The results are presented in 
Table 6-III. 
Table 6-III 
Effect of peptide 401, melittin and indomethacin 
on cell viability after lh incubation 
Control 
Melittin (0.5 mg/ml) 
Indomethacin (0.033 mg/ml) 
401 (1.25 mg/ml) 
401 (0.625 mg/ml) 
401 (0.125 mg/ml) 
401 (0.0625 mg/ml) 
Blank (850 C for 2 min) 
F.I. 
(3 min after 
adding FDA) 
36.7 
9.5 
34.5 
47.5 
33.5 
33.5 
31.5 
1.5 
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The results in Table 6-III show that peptide 401 has no cytotoxic effects 
on the cell population obtained from the rat peritoneum exudate after 
1 h incubation. Melittin however seems to be much more toxic to the 
peritoneum cells than to the mesenteric lymphocytes. 
6-4 . Discussion 
In the present work, experiments were carried out in order to 
investigate if the anti-inflammatory activity of peptide 401 in the rat 
adjuvant polyarthritis could be explained by a direct action on the 
lymphocytes, as reflected by suppression of lymphocyte activation. 
Peptide 401 tested in a concentration range of 0.5 - 100 ŸŦIÜŨĚdid not 
show any significant effects on lymphocyte activation, as shown by 
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3H-thymidine incorporation. The observed suppression of 3H-thymidine 
incorporation by lymphocytes incubated with peptide 401 in concentrations 
of 0.1 mg/ml, in the absence of PHA, .02( P < .01, indicated the possibility 
of some cytotoxic effects, since this suppression was not as significant 
when the cells were stimulated by PHA. Such a conclusion is supported 
by the results of the cytotoxic tests carried out with the rat lymphocytes, 
which showed that concentrations of peptide 401 of approximately the 
3 . 
. same order as the ones that produced a reduction in H-thymidine 
incorporation, were able to cause a 43% decrease in the rate of 
fluorescein formation by the membrane est erases of the lymphocytes. The 
cytotoxic effects of peptide 401 on the lymphocytes could only be observed 
after incubation with the cells for 22 h and as in the experiments 
3 involving H-thymidine incorporation, peptide 401 stays in contact with 
3 the cells for at least 48 h, the reduced incorporation of ÑŸWUXÜÙTÙŪŤĚ
by the lymphocytes in the absence of PHA is presumably due to effects of 
peptide 401 on the membranes. Why the group of cells incubated with 
peptide 401 in the presence of PHA is less affected, remains unclear. 
It is possible that the cell agglutination caused by PHA allowed a 
smaller area of the membrane to be exposed to peptide 401. Experiments 
performed by G. Atkinson (13) using rat polymorphonucleocytes showed 
that peptide 401 in concentra1;ions 01' U.l mg/ml had some cytotoXic 
effects (measured by LDH release). However, in the present experiments, 
no cytotoxic effects due to peptide 401 could be observed after 1 h 
incubation with a population of leucocytes obtained from the rat 
... 
peritoneum. 
It should be pointed out that peptide 401, in the concentration 
range tested, did not enhance the blastogenesis i.nduced by ÖÑĻŸĚ This 
differs from the effects of other basic polypeptides which were shown to 
potentiate the action of phytomitogens (124). The possibility that 
peptide 401 could be interfering with the inhibitory action of PGE1 , 
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by forming complexes due to its basicity, was ruled out since the 
present experiments show that there is no difference between the groups 
incubated with PGE1 alone and those in which PGE1 was incubated together 
with peptide 401. 
Considering that peptide 401 had also no effects in vitro on 
human lymphocyte activation by PHA, and in antibody production by mouse 
lymphocytes in a Jerne plaque assay (169), the possibility that the 
anti-inflammatory activity of peptide 401 in the rat adjuvant poly-
arthritis is mediated through effects on lymphocytes seems remote. 
However, it should be kept in mind that peptide 401 may have a different 
effect in vivo. Furthermore, the possibility still remains that peptide 
401, like other anti-inflammatory agents (76), may act on the lymphocytes 
inhibiting their migration in vivo, since it was demonstrated that d-401 
was able to bind to lymphocytes and that peptide 401 caused some 
cytotoXic effects on lymphocytes. 
.-
. " . 
Summary and Conclusions 
1 - Experiments in vitro showed that peptide 401 was able to inhibit 
the synthesis of PGE2, using an enzymatic complex obtained from 
sheep seminal vesicles. As prostaglandins are important mediators 
of inflammation in the model used to assay the anti-inflammatory 
activity of peptide 401 it was concluded that inhibition of 
prostaglandin synthesis could explain the therapeutic action of' 
peptide 401 in the rat carrageenan oedema. 
2 - Dansy1ated peptide 401 was shown to bind preferentially to rat 
leucocytes, when incubated with a population of rat blood cells. 
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This fact together with the notion that rat leucocytes are regarded 
as major sources of prostaglandins during the carrageenan oedema, 
and that the maximum anti-inflammatory activity of peptide 401 
COincides with leucocyte migration to the site of inflammation,. 
support the idea that peptide 401 derives its. anti-inflammatory 
activity through inhibition of prostaglandin synthesis by the rat 
leucocytes. 
3 - The same pharmacological effects of peptide 401 could be involved 
in the rat adjuvant arthritis where peptide 401 also shows anti-
. 
inflammatory activity. In this experimental model, the lymphocytes 
are suspected to play an important role. As it was shown that d-401 
was also able to bind to lymphocytes (not so strongly as to mast 
cells), the possible influence of peptide 401 on the activation of 
lymphocytes was studied. However, the results of these experiments 
indicated that peptide 401 had no effects on lymphocytes, apart 
from slight cytotoxicity. Therefore, it is unlikely that the anti-
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inflammatory activity of peptide 401, either in the acute model of 
the carrageenan oedema or in the adjuvant arthritis, is mediated by 
any effects on lymphocytes. 
4 - The experiments with the liposomes were carried out in order to 
determine if the lipids of the membranes were important for the 
binding of peptide 401 to the leucocytes. It was found that the 
ratio between cholesterol and the phospholipids was important for 
the observed effects of peptide 401 in increasing the permeability 
22 + 22 + 
rates to Na. The increased Na permeability induced by peptide 
401, which did not seem to be a consequence of lytic effects could 
have implications in the ability of peptide 401 to degranu1ate mast 
cells, since this could involve an exchange of cations. 
5 - The possibility that the anti-inflammatory activity of peptide 401 
could be mediated by a direct stimulation of corticosterone production 
by the rat adrenal glands was ruled out since no such effects could 
.be detected. However, the possibility exists that peptide 401 may 
act on the rat adenohypophysis, stimulating the release of ACTH. 
The present work consisted of a series of in vitro tests. 
These were attempts to isolate some events interconnected in the process 
of inflammation. However, because these isolated systems lack the degree 
of organization and hence the controlling factors present in the general 
process, it must be kept in mind that any conclusions derived from such 
experiments are necessarily oversimplifications. 
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